Buy JWH-210 Online Premium Powder For Sale - Revision history

https://whdc.ac/index.php?action=history&feed=atom&title=Buy_JWH-210_Online_Premium_Powder_For_Sale Buy JWH-210 Online Premium Powder For Sale - Revision history 2026-05-26T00:25:31Z Revision history for this page on the wiki MediaWiki 1.43.5 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=225267&oldid=prev DamonAngas210 at 09:52, 24 May 2026 2026-05-24T09:52:07Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:52, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of </del>a <del style="font-weight: bold; text-decoration: none;">broad spectrum </del>of <del style="font-weight: bold; text-decoration: none;">recreational drugs</del>, <del style="font-weight: bold; text-decoration: none;">including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on </del>the <del style="font-weight: bold; text-decoration: none;">urine of the patient</del>. <del style="font-weight: bold; text-decoration: none;">He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before </del>the <del style="font-weight: bold; text-decoration: none;">onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific</del>, <del style="font-weight: bold; text-decoration: none;">transient symptoms, clinical recognition </del>of <del style="font-weight: bold; text-decoration: none;">SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the [https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb.com/ 4F ADB] presence </del>and <del style="font-weight: bold; text-decoration: none;">elution profiles of nicotine and ADB-BUTINACA </del>in the <del style="font-weight: bold; text-decoration: none;">analysed vape liquid sample. LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS Chromatograms of Nicotine (Top</del>) <del style="font-weight: bold; text-decoration: none;">and ADB-BUTINACA </del>(<del style="font-weight: bold; text-decoration: none;">Bottom</del>) <del style="font-weight: bold; text-decoration: none;">in </del>the <del style="font-weight: bold; text-decoration: none;">Vape Liquid used by </del>the <del style="font-weight: bold; text-decoration: none;">patient</del>. <del style="font-weight: bold; text-decoration: none;">The LC-QTOF-MS analysis showed </del>that <del style="font-weight: bold; text-decoration: none;">the e</del>-<del style="font-weight: bold; text-decoration: none;">liquid contained nicotine and ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA </del>(<del style="font-weight: bold; text-decoration: none;">Fig. 1</del>). <del style="font-weight: bold; text-decoration: none;">Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances</del>, <del style="font-weight: bold; text-decoration: none;">the liquid </del>of the <del style="font-weight: bold; text-decoration: none;">e-cigarette was thereafter screened using liquid chromatography-quadrupole time-</del>of<del style="font-weight: bold; text-decoration: none;">-flight mass spectrometry </del>(<del style="font-weight: bold; text-decoration: none;">LC-QTOF-MS</del>) <del style="font-weight: bold; text-decoration: none;">on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom</del><br><br><br><del style="font-weight: bold; text-decoration: none;">When clinical presentation </del>and<del style="font-weight: bold; text-decoration: none;">/or initial DOA testing results are inconclusive</del>, <del style="font-weight: bold; text-decoration: none;">additional testing with LC-QTOF-MS can be valuable and is recommended</del>. <del style="font-weight: bold; text-decoration: none;">SCRAs and </del>other <del style="font-weight: bold; text-decoration: none;">NPS may not be detected by point-</del>of<del style="font-weight: bold; text-decoration: none;">-care DOA tests. In this case, the point-</del>of<del style="font-weight: bold; text-decoration: none;">-care DOA urine screening was not able to detect </del>the synthetic <del style="font-weight: bold; text-decoration: none;">cannabinoid ADB-BUTINAC<br><br>Legal status <br>JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds </del>that are <del style="font-weight: bold; text-decoration: none;">consistent </del>and <del style="font-weight: bold; text-decoration: none;">dependable</del>, <del style="font-weight: bold; text-decoration: none;">and this product delivers on both fronts</del>. <del style="font-weight: bold; text-decoration: none;">Whether used in small</del>-<del style="font-weight: bold; text-decoration: none;">scale experiments </del>or <del style="font-weight: bold; text-decoration: none;">larger research projects, the compound maintains its integrity under recommended storage conditions</del>. <del style="font-weight: bold; text-decoration: none;">This ensures ease </del>of <del style="font-weight: bold; text-decoration: none;">handling and precise measurement during laboratory use. Each batch undergoes detailed verification </del>to <del style="font-weight: bold; text-decoration: none;">ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant </del>(<del style="font-weight: bold; text-decoration: none;">13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food </del>and <del style="font-weight: bold; text-decoration: none;">Drug Safety</del>, <del style="font-weight: bold; text-decoration: none;">Republic of Kore</del><br><br><br><del style="font-weight: bold; text-decoration: none;">As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally</del>, <del style="font-weight: bold; text-decoration: none;">clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests</del>. <del style="font-weight: bold; text-decoration: none;">He confirmed that he had been vaping an electronic cigarette </del>(<del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette) earlier that day just before </del>the <del style="font-weight: bold; text-decoration: none;">onset of his symptoms. Metabolic acidosis </del>(<del style="font-weight: bold; text-decoration: none;">1/3, 0</del>/<del style="font-weight: bold; text-decoration: none;">7</del>) and <del style="font-weight: bold; text-decoration: none;">respiratory acidosis </del>(<del style="font-weight: bold; text-decoration: none;">1/3, 0</del>/<del style="font-weight: bold; text-decoration: none;">7</del>)<del style="font-weight: bold; text-decoration: none;">, All 10 patients recovered </del>with <del style="font-weight: bold; text-decoration: none;">supportive care</del>, <del style="font-weight: bold; text-decoration: none;">including intubation and ventilation for one case</del>. <del style="font-weight: bold; text-decoration: none;">In 3 cases ADB-BUTINACA was the only substance detected</del>, <del style="font-weight: bold; text-decoration: none;">while in seven other substances of misuse were also detected including other SCRA</del>, <del style="font-weight: bold; text-decoration: none;">opioids</del>, <del style="font-weight: bold; text-decoration: none;">benzodiazepines cocaine and pregabali<br><br>5F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">PINACA </del>(<del style="font-weight: bold; text-decoration: none;">also known as 5F-ADB</del>, <del style="font-weight: bold; text-decoration: none;">5F-ADB-PINACA)</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-CHIMICA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">ADB-FUBINACA</del>, and <del style="font-weight: bold; text-decoration: none;">AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA </del>(<del style="font-weight: bold; text-decoration: none;">also known </del>as <del style="font-weight: bold; text-decoration: none;">FUB</del>-<del style="font-weight: bold; text-decoration: none;">AMB, MMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA) </del>were <del style="font-weight: bold; text-decoration: none;">tested for </del>in <del style="font-weight: bold; text-decoration: none;">vivo cannabinoid-like effects to assess their abuse liabilit</del><br><br><del style="font-weight: bold; text-decoration: none;">As most </del>of the <del style="font-weight: bold; text-decoration: none;">urine samples obtained in this study were found </del>to <del style="font-weight: bold; text-decoration: none;">contain other SCBs’ metabolites and other drugs</del>, <del style="font-weight: bold; text-decoration: none;">the urinary profile of the three individual urine samples that encompass 4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-BINACA metabolites exclusively (Table 3) is worth considering when selecting a suitable urinary marke</del><br><br><br><del style="font-weight: bold; text-decoration: none;">Demographic </del>and <del style="font-weight: bold; text-decoration: none;">clinical features are recorded and blood and/or urine samples analysed </del>using <del style="font-weight: bold; text-decoration: none;">high</del>-<del style="font-weight: bold; text-decoration: none;">resolution accurate mass liquid chromatography-mass spectrometry</del>. The <del style="font-weight: bold; text-decoration: none;">authors declare that they have no </del>known <del style="font-weight: bold; text-decoration: none;">competing financial interests or personal relationships that could have appeared </del>to <del style="font-weight: bold; text-decoration: none;">influence the work reported in this paper. Second</del>, <del style="font-weight: bold; text-decoration: none;">we could not 4F ADB retrieve further detailed information about </del>the <del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette that was used by the patient such as the label or the region </del>of <del style="font-weight: bold; text-decoration: none;">origin. Whether a recreational drug can be administered via vaping</del>, <del style="font-weight: bold; text-decoration: none;">depends on whether </del>the <del style="font-weight: bold; text-decoration: none;">drug becomes volatile under the evaporation temperature </del>of <del style="font-weight: bold; text-decoration: none;">the e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette. Of </del>these <del style="font-weight: bold; text-decoration: none;">samples</del>, <del style="font-weight: bold; text-decoration: none;">22 contained one </del>or <del style="font-weight: bold; text-decoration: none;">more SCRAs</del>, <del style="font-weight: bold; text-decoration: none;">THC was only detected </del>in <del style="font-weight: bold; text-decoration: none;">11 samples</del>, <del style="font-weight: bold; text-decoration: none;">only one contained cannabidiol and 6 contained a mixture </del>of <del style="font-weight: bold; text-decoration: none;">THC </del>and <del style="font-weight: bold; text-decoration: none;">cannabidiol</del>. <del style="font-weight: bold; text-decoration: none;">There is difficulty in finding the right information about the NPS, defining their potency </del>and <del style="font-weight: bold; text-decoration: none;">confirmation </del>of <del style="font-weight: bold; text-decoration: none;">their existence in e-liquids or urine samples</del>.<br><del style="font-weight: bold; text-decoration: none;">Data availabili</del><br><br><del style="font-weight: bold; text-decoration: none;"><br>LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS represents a significant advancement </del>in the <del style="font-weight: bold; text-decoration: none;">field </del>of <del style="font-weight: bold; text-decoration: none;">drug detection, offering higher sensitivity, specificity, and </del>a <del style="font-weight: bold; text-decoration: none;">broader spectrum of detectable substances</del>. <del style="font-weight: bold; text-decoration: none;">Despite </del>all <del style="font-weight: bold; text-decoration: none;">negative results </del>in <del style="font-weight: bold; text-decoration: none;">the point</del>-of-<del style="font-weight: bold; text-decoration: none;">care test for recreational drugs</del>, <del style="font-weight: bold; text-decoration: none;">the liquid chromatography-quadrupole time</del>-of<del style="font-weight: bold; text-decoration: none;">-flight mass spectrometry (LC-QTOF-MS) analysis showed that </del>the <del style="font-weight: bold; text-decoration: none;">liquid of </del>the <del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette contained ADB-BUTINACA</del>, <del style="font-weight: bold; text-decoration: none;">a synthetic cannabinoid</del>. <del style="font-weight: bold; text-decoration: none;">We report a 27</del>-<del style="font-weight: bold; text-decoration: none;">year-old man who was admitted to the emergency room because of sudden 4F ADB headache</del>, <del style="font-weight: bold; text-decoration: none;">nausea</del>, <del style="font-weight: bold; text-decoration: none;">vertigo</del>, <del style="font-weight: bold; text-decoration: none;">red eyes </del>and <del style="font-weight: bold; text-decoration: none;">palpitations</del>. <del style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids are gaining popularity globally </del>and <del style="font-weight: bold; text-decoration: none;">detection </del>is <del style="font-weight: bold; text-decoration: none;">not commonly availabl</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Figure 1. <br>Each training session lasted </ins>a <ins style="font-weight: bold; text-decoration: none;">maximum </ins>of <ins style="font-weight: bold; text-decoration: none;">10 min</ins>, <ins style="font-weight: bold; text-decoration: none;">and </ins>the <ins style="font-weight: bold; text-decoration: none;">rats could earn up to 20 food pellets</ins>. <ins style="font-weight: bold; text-decoration: none;">Thirty minutes prior to </ins>the <ins style="font-weight: bold; text-decoration: none;">training sessions</ins>, <ins style="font-weight: bold; text-decoration: none;">rats received an injection </ins>of <ins style="font-weight: bold; text-decoration: none;">either vehicle or Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC </ins>and <ins style="font-weight: bold; text-decoration: none;">were subsequently placed </ins>in the <ins style="font-weight: bold; text-decoration: none;">behavior-testing chambers, where food (45</ins>-<ins style="font-weight: bold; text-decoration: none;">mg food pellets; Bio</ins>-<ins style="font-weight: bold; text-decoration: none;">Serve, Frenchtown, NJ</ins>) <ins style="font-weight: bold; text-decoration: none;">was available as a reinforcer for every ten responses </ins>(<ins style="font-weight: bold; text-decoration: none;">FR10</ins>) <ins style="font-weight: bold; text-decoration: none;">on a designated injection appropriate lever. A houselight was centered over the hopper close to </ins>the <ins style="font-weight: bold; text-decoration: none;">ceiling and was illuminated only when </ins>the <ins style="font-weight: bold; text-decoration: none;">levers were active</ins>. <ins style="font-weight: bold; text-decoration: none;">Each dose range included doses </ins>that <ins style="font-weight: bold; text-decoration: none;">were without effect to those producing at least 50% depression compared to vehicle control. Twenty</ins>-<ins style="font-weight: bold; text-decoration: none;">four male Sprague</ins>-<ins style="font-weight: bold; text-decoration: none;">Dawley rats were obtained from Envigo </ins>(<ins style="font-weight: bold; text-decoration: none;">Houston, TX</ins>). <ins style="font-weight: bold; text-decoration: none;">Male ND4 Swiss–Webster mice were obtained from Envigo (Houston</ins>, <ins style="font-weight: bold; text-decoration: none;">TX) at approximately 8 weeks </ins>of <ins style="font-weight: bold; text-decoration: none;">age and maintained in </ins>the <ins style="font-weight: bold; text-decoration: none;">University </ins>of <ins style="font-weight: bold; text-decoration: none;">North Texas Health Science Center </ins>(<ins style="font-weight: bold; text-decoration: none;">UNTHSC</ins>) <ins style="font-weight: bold; text-decoration: none;">animal facility for two weeks prior to testin</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">Acute kidney damage </ins>and <ins style="font-weight: bold; text-decoration: none;">even kidney failure have been reported following use of synthetic cannabinoids (Davidson, et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2017)</ins>. <ins style="font-weight: bold; text-decoration: none;">One recent study has looked at </ins>other <ins style="font-weight: bold; text-decoration: none;">mechanisms </ins>of <ins style="font-weight: bold; text-decoration: none;">action in some </ins>of the <ins style="font-weight: bold; text-decoration: none;">older </ins>synthetic <ins style="font-weight: bold; text-decoration: none;">cannabinoids and reported </ins>that <ins style="font-weight: bold; text-decoration: none;">some produced varying amounts of activity at sites which </ins>are <ins style="font-weight: bold; text-decoration: none;">related to cardiotoxicity </ins>and <ins style="font-weight: bold; text-decoration: none;">heart disease (Wiley et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2016)</ins>. <ins style="font-weight: bold; text-decoration: none;">It is not known whether the increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC </ins>or <ins style="font-weight: bold; text-decoration: none;">whether these "super-strength" cannabinoids produce effects at other receptors</ins>. <ins style="font-weight: bold; text-decoration: none;">A major cause of concern is that some </ins>of <ins style="font-weight: bold; text-decoration: none;">the more recently seen synthetic cannabinoids are more likely </ins>to <ins style="font-weight: bold; text-decoration: none;">produce extremely toxic effects than the older synthetics </ins>(<ins style="font-weight: bold; text-decoration: none;">Tai </ins>and <ins style="font-weight: bold; text-decoration: none;">Fantegrossi</ins>, <ins style="font-weight: bold; text-decoration: none;">2017</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">Similarly</ins>, <ins style="font-weight: bold; text-decoration: none;"> [https://cannabinoidsrc4f-adb</ins>.<ins style="font-weight: bold; text-decoration: none;">com/ adb butinaca] precursor ion identified at m/z 380 </ins>(<ins style="font-weight: bold; text-decoration: none;">B19/B21, B23/B25) was 16 Da higher than the 4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB-BINACA, indicating monohydroxylation at </ins>the <ins style="font-weight: bold; text-decoration: none;">butyl side chain </ins>(<ins style="font-weight: bold; text-decoration: none;">B19</ins>/<ins style="font-weight: bold; text-decoration: none;">B21</ins>) and <ins style="font-weight: bold; text-decoration: none;">indazole </ins>(<ins style="font-weight: bold; text-decoration: none;">B23</ins>/<ins style="font-weight: bold; text-decoration: none;">B25</ins>) <ins style="font-weight: bold; text-decoration: none;">moieties </ins>with <ins style="font-weight: bold; text-decoration: none;">product ions m/z 145 and 161</ins>, <ins style="font-weight: bold; text-decoration: none;">respectively</ins>. <ins style="font-weight: bold; text-decoration: none;">Metabolites identified at m/z 366 (B8</ins>, <ins style="font-weight: bold; text-decoration: none;">B9</ins>, <ins style="font-weight: bold; text-decoration: none;">B13)</ins>, <ins style="font-weight: bold; text-decoration: none;">which was 16 Da higher than the 4F</ins>-MDMB-<ins style="font-weight: bold; text-decoration: none;">BINACA ester hydrolysis metabolite </ins>(<ins style="font-weight: bold; text-decoration: none;">B22), confirmed monohydroxylation upon ester hydrolysis. Death involving these drugs have been reported [5</ins>,<ins style="font-weight: bold; text-decoration: none;">6</ins>,<ins style="font-weight: bold; text-decoration: none;">7</ins>,<ins style="font-weight: bold; text-decoration: none;">8</ins>,<ins style="font-weight: bold; text-decoration: none;">9]</ins>, and <ins style="font-weight: bold; text-decoration: none;">this raises public health and social concerns. Due to their similar physiological effects to the principal psychoactive component of cannabis, Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol </ins>(<ins style="font-weight: bold; text-decoration: none;">THC), SCBs are gaining popularity and are often abused </ins>as <ins style="font-weight: bold; text-decoration: none;">recreational drugs. The fact that similar 4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA and ethanol concentrations </ins>were <ins style="font-weight: bold; text-decoration: none;">detected in the postmortem blood samples of both victims suggests that both substances played a role </ins>in <ins style="font-weight: bold; text-decoration: none;">the fatal outcom</ins><br><br><ins style="font-weight: bold; text-decoration: none;">55 % </ins>of the <ins style="font-weight: bold; text-decoration: none;">patients required a longer admission due </ins>to <ins style="font-weight: bold; text-decoration: none;">symptoms such as severe tachycardia, hypertensive crise, convulsions</ins>, <ins style="font-weight: bold; text-decoration: none;">acute kidney insufficiency but also long</ins>-<ins style="font-weight: bold; text-decoration: none;">lasting, severe psychological problems</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo </ins>and <ins style="font-weight: bold; text-decoration: none;">various in-vitro models, studies were either conducted </ins>using <ins style="font-weight: bold; text-decoration: none;">small in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons </ins>. The <ins style="font-weight: bold; text-decoration: none;">hepatic cell line HepG2 is often used as an initial screen as it is </ins>known to <ins style="font-weight: bold; text-decoration: none;">produce high reproducibility results with relatively stable enzyme concentration</ins>, <ins style="font-weight: bold; text-decoration: none;">although they are limited by </ins>the <ins style="font-weight: bold; text-decoration: none;">low</ins>-<ins style="font-weight: bold; text-decoration: none;">level expression </ins>of <ins style="font-weight: bold; text-decoration: none;">several metabolizing enzymes</ins>, <ins style="font-weight: bold; text-decoration: none;">including </ins>the <ins style="font-weight: bold; text-decoration: none;">cytochrome P450 (CYP) class </ins>of <ins style="font-weight: bold; text-decoration: none;">proteins [17, 18]. In</ins>-<ins style="font-weight: bold; text-decoration: none;">vitro metabolism studies are generally used to complement </ins>these <ins style="font-weight: bold; text-decoration: none;">data using perfused organs</ins>, <ins style="font-weight: bold; text-decoration: none;">tissue </ins>or <ins style="font-weight: bold; text-decoration: none;">cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15</ins>,<ins style="font-weight: bold; text-decoration: none;">16]. Since most SCBs are found extensively in metabolized forms </ins>in <ins style="font-weight: bold; text-decoration: none;">urine</ins>, <ins style="font-weight: bold; text-decoration: none;">the identification of metabolites is </ins>of <ins style="font-weight: bold; text-decoration: none;">vital importance for forensic </ins>and <ins style="font-weight: bold; text-decoration: none;">clinical toxicologists</ins>. <ins style="font-weight: bold; text-decoration: none;">Identifying SCB intake </ins>and <ins style="font-weight: bold; text-decoration: none;">its correlating specific adverse effects require rapid elucidation </ins>of <ins style="font-weight: bold; text-decoration: none;">these SCBs</ins>. <ins style="font-weight: bold; text-decoration: none;">The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA </ins>in <ins style="font-weight: bold; text-decoration: none;">abundance but </ins>the <ins style="font-weight: bold; text-decoration: none;">rest </ins>of <ins style="font-weight: bold; text-decoration: none;">the metabolites were found in </ins>a <ins style="font-weight: bold; text-decoration: none;">small amount</ins>. <ins style="font-weight: bold; text-decoration: none;">Elegans and HLM models detected </ins>all <ins style="font-weight: bold; text-decoration: none;">of the </ins>in-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites (100%), whilst HepG2 cells detected 7 out </ins>of <ins style="font-weight: bold; text-decoration: none;">the 8 in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites (87.5%). Hence</ins>, <ins style="font-weight: bold; text-decoration: none;">structural elucidation could not be confirmed unless a reference standard is made availabl<br><br><br>This makes JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 powder one </ins>of the <ins style="font-weight: bold; text-decoration: none;">most powerful compounds in its class, often used in incense blends and research settings. Our commitment to quality and customer satisfaction makes us </ins>the <ins style="font-weight: bold; text-decoration: none;">best place for jwh 210 buy</ins>-<ins style="font-weight: bold; text-decoration: none;">whether you need it for research, incense blends</ins>, <ins style="font-weight: bold; text-decoration: none;">or other legal applications</ins>. <ins style="font-weight: bold; text-decoration: none;">For qualified professionals, investing in high</ins>-<ins style="font-weight: bold; text-decoration: none;">quality</ins>, <ins style="font-weight: bold; text-decoration: none;">verified material ensures accuracy</ins>, <ins style="font-weight: bold; text-decoration: none;">safety</ins>, and <ins style="font-weight: bold; text-decoration: none;">regulatory compliance</ins>. <ins style="font-weight: bold; text-decoration: none;">Prioritize vendors providing full analytical validation, transparent documentation, </ins>and <ins style="font-weight: bold; text-decoration: none;">compliance with international controls. Value </ins>is <ins style="font-weight: bold; text-decoration: none;">best assessed through consistency, verifiable purity, and regulatory compliance—not cost alon</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=225208&oldid=prev DamonAngas210 at 09:46, 24 May 2026 2026-05-24T09:46:36Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:46, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Demographic and clinical features are recorded and blood and/or urine samples analysed using high-</del>resolution <del style="font-weight: bold; text-decoration: none;">accurate mass liquid chromatography-</del>mass spectrometry<del style="font-weight: bold; text-decoration: none;">. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb.com retrieve further detailed information about the e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette that was used by </del>the <del style="font-weight: bold; text-decoration: none;">patient such as the label or the region </del>of <del style="font-weight: bold; text-decoration: none;">origin. Whether </del>a recreational <del style="font-weight: bold; text-decoration: none;">drug can be administered via vaping</del>, <del style="font-weight: bold; text-decoration: none;">depends </del>on <del style="font-weight: bold; text-decoration: none;">whether </del>the <del style="font-weight: bold; text-decoration: none;">drug becomes volatile under </del>the <del style="font-weight: bold; text-decoration: none;">evaporation temperature </del>of <del style="font-weight: bold; text-decoration: none;">the </del>e-cigarette. <del style="font-weight: bold; text-decoration: none;">Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained </del>a <del style="font-weight: bold; text-decoration: none;">mixture </del>of <del style="font-weight: bold; text-decoration: none;">THC </del>and <del style="font-weight: bold; text-decoration: none;">cannabidiol</del>. <del style="font-weight: bold; text-decoration: none;">There is difficulty in finding the right information about the NPS</del>, <del style="font-weight: bold; text-decoration: none;">defining their potency and confirmation </del>of <del style="font-weight: bold; text-decoration: none;">their existence in e-liquids or urine samples</del>.<br>Data <del style="font-weight: bold; text-decoration: none;">availabili</del><br><del style="font-weight: bold; text-decoration: none;"><br><br>Thirty minutes prior to </del>the <del style="font-weight: bold; text-decoration: none;">training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers</del>, <del style="font-weight: bold; text-decoration: none;">where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over </del>the <del style="font-weight: bold; text-decoration: none;">hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). </del>[https://cannabinoidsrc4f-adb.com/ <del style="font-weight: bold; text-decoration: none;">cannabinoidsrc4f-adb.com</del>] <del style="font-weight: bold; text-decoration: none;">Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks </del>of <del style="font-weight: bold; text-decoration: none;">age </del>and <del style="font-weight: bold; text-decoration: none;">maintained </del>in the <del style="font-weight: bold; text-decoration: none;">University </del>of <del style="font-weight: bold; text-decoration: none;">North Texas Health Science Center </del>(<del style="font-weight: bold; text-decoration: none;">UNTHSC</del>) <del style="font-weight: bold; text-decoration: none;">animal facility for two weeks prior to testin<br><br>Metabolic Profile of Synthetic Cannabinoids 5F</del>-<del style="font-weight: bold; text-decoration: none;">PB</del>-<del style="font-weight: bold; text-decoration: none;">22, PB</del>-<del style="font-weight: bold; text-decoration: none;">22, XLR</del>-<del style="font-weight: bold; text-decoration: none;">11 </del>and <del style="font-weight: bold; text-decoration: none;">UR</del>-<del style="font-weight: bold; text-decoration: none;">144 by Cunninghamella elegans <br>The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour </del>(<del style="font-weight: bold; text-decoration: none;">intake route, amount of drug and intake frequency</del>)<del style="font-weight: bold; text-decoration: none;">, time from last drug intake and metabolic stability</del>. <del style="font-weight: bold; text-decoration: none;">This indicated that </del>the <del style="font-weight: bold; text-decoration: none;">phase I metabolism </del>of <del style="font-weight: bold; text-decoration: none;">4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-BINACA are unlikely </del>to <del style="font-weight: bold; text-decoration: none;">be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite</del>, the <del style="font-weight: bold; text-decoration: none;">second major metabolite after monohydroxylation in </del>the <del style="font-weight: bold; text-decoration: none;">C. Ester hydrolysis with dehydrogenation formed in</del>-<del style="font-weight: bold; text-decoration: none;">vivo in this study </del>was <del style="font-weight: bold; text-decoration: none;">also reported among other indazole carboxamide type SCBs with tert</del>-<del style="font-weight: bold; text-decoration: none;">leucine methyl ester moieties such as 5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA and MDMB</del>-<del style="font-weight: bold; text-decoration: none;">4en</del>-<del style="font-weight: bold; text-decoration: none;">PINACA [39, 40]</del>. <del style="font-weight: bold; text-decoration: none;">Similar to </del>the <del style="font-weight: bold; text-decoration: none;">in-vivo findings</del>, <del style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA ester hydrolysis (B22) was </del>the <del style="font-weight: bold; text-decoration: none;">major metabolite for both HepG2 </del>and <del style="font-weight: bold; text-decoration: none;">HLM models, consistent with </del>the <del style="font-weight: bold; text-decoration: none;">known hydrolytic activity of CES reported</del><br><br><del style="font-weight: bold; text-decoration: none;">4. Drugs </del><br><del style="font-weight: bold; text-decoration: none;">The purpose </del>of the <del style="font-weight: bold; text-decoration: none;">present study </del>was to <del style="font-weight: bold; text-decoration: none;">assess </del>the <del style="font-weight: bold; text-decoration: none;">abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, </del>ADB-<del style="font-weight: bold; text-decoration: none;">FUBINACA, and AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA</del>. <del style="font-weight: bold; text-decoration: none;">The findings produce an apparent paradox</del>, <del style="font-weight: bold; text-decoration: none;">since CPP </del>and <del style="font-weight: bold; text-decoration: none;">self</del>-<del style="font-weight: bold; text-decoration: none;">administration predict with high reliability </del>the <del style="font-weight: bold; text-decoration: none;">likelihood that a </del>compound <del style="font-weight: bold; text-decoration: none;">will be abused by humans</del>, and <del style="font-weight: bold; text-decoration: none;">cannabinoids are well-known to produce active drug-seeking in humans</del>. <del style="font-weight: bold; text-decoration: none;">Drug discrimination is </del>a <del style="font-weight: bold; text-decoration: none;">well-known animal model </del>of the <del style="font-weight: bold; text-decoration: none;">subjective effects </del>of <del style="font-weight: bold; text-decoration: none;">drugs </del>and <del style="font-weight: bold; text-decoration: none;">correlates well with abuse liability (Young 2009; Horton et al. 2013). Assessment of abuse liability is based on several factors</del>, <del style="font-weight: bold; text-decoration: none;">including chemical structure, pharmacological mechanism </del>of <del style="font-weight: bold; text-decoration: none;">action, </del>and <del style="font-weight: bold; text-decoration: none;">finally</del>, <del style="font-weight: bold; text-decoration: none;">subjective and reinforcing behavioral effects (FDA, 2010; Swedberg, 2013).</del><br><del style="font-weight: bold; text-decoration: none;">Michael B Gat</del><br><br>As <del style="font-weight: bold; text-decoration: none;">previously mentioned</del>, <del style="font-weight: bold; text-decoration: none;">all </del>of the <del style="font-weight: bold; text-decoration: none;">compounds tested </del>in <del style="font-weight: bold; text-decoration: none;">the present study </del>(<del style="font-weight: bold; text-decoration: none;">MDMB</del>-PINACA, MDMB-<del style="font-weight: bold; text-decoration: none;">CHMICA</del>, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA<del style="font-weight: bold; text-decoration: none;">) act </del>as <del style="font-weight: bold; text-decoration: none;">agonists at CB1 receptors (Banister et al.</del>, <del style="font-weight: bold; text-decoration: none;">2015, 2016; Gamage et al., 2018</del>)<del style="font-weight: bold; text-decoration: none;">, which suggests these compounds will produce Δ9-THC</del>-like effects<del style="font-weight: bold; text-decoration: none;">, including </del>abuse liabilit<br><br><del style="font-weight: bold; text-decoration: none;"><br>After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL </del>of the <del style="font-weight: bold; text-decoration: none;">supernatant was directly injected </del>to the <del style="font-weight: bold; text-decoration: none;">chromatographic system. In </del>the <del style="font-weight: bold; text-decoration: none;">next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex</del>-<del style="font-weight: bold; text-decoration: none;">mixing, the mixture was allowed to stand cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb.com at room temperature for 5 min. MS/MS experiments were performed in MRM </del>(<del style="font-weight: bold; text-decoration: none;">multiple reaction monitoring</del>) <del style="font-weight: bold; text-decoration: none;">mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates</del><br><br><del style="font-weight: bold; text-decoration: none;">Eight in</del>-<del style="font-weight: bold; text-decoration: none;">vivo metabolites tentatively identified were mainly products of ester hydrolysis with </del>or <del style="font-weight: bold; text-decoration: none;">without additional dehydrogenation</del>, <del style="font-weight: bold; text-decoration: none;">N-dealkylation, monohydroxylation and oxidative defluorination with </del>further <del style="font-weight: bold; text-decoration: none;">oxidation to butanoic aci<br><br><br>In summary, JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 Chemical Powder stands out </del>as a <del style="font-weight: bold; text-decoration: none;">high</del>-<del style="font-weight: bold; text-decoration: none;">quality research compound designed for professionals who demand accuracy</del>, <del style="font-weight: bold; text-decoration: none;">consistency</del>, and <del style="font-weight: bold; text-decoration: none;">reliability. This commitment to cannabinoidsrc4f-adb.com quality makes it </del>a <del style="font-weight: bold; text-decoration: none;">trusted option for professionals who require dependable compounds for their work</del>. <del style="font-weight: bold; text-decoration: none;">From sourcing raw materials to final packaging</del>, <del style="font-weight: bold; text-decoration: none;">every stage </del>of <del style="font-weight: bold; text-decoration: none;">the process is monitored to ensure compliance with laboratory</del>-<del style="font-weight: bold; text-decoration: none;">grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards</del>.<br><del style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </del><br><del style="font-weight: bold; text-decoration: none;">Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH-210 cannabinoidsrc4f-adb.com should be considered.</del><br><del style="font-weight: bold; text-decoration: none;">How to Choose Powder JWH-210 </del><br><del style="font-weight: bold; text-decoration: none;">When learning how to choose powder JWH</del>-<del style="font-weight: bold; text-decoration: none;">210, the most critical factor is verifying high chemical purity (≥98%) from </del>a <del style="font-weight: bold; text-decoration: none;">reputable supplier with independent lab testing. We also demonstrated that JWH-210 administration resulted </del>in the <del style="font-weight: bold; text-decoration: none;">decrease </del>of <del style="font-weight: bold; text-decoration: none;">expression levels of T-cell activator including Cd3e</del>, <del style="font-weight: bold; text-decoration: none;">Cd3g</del>, <del style="font-weight: bold; text-decoration: none;">Cd74p31</del>, and <del style="font-weight: bold; text-decoration: none;">Cd74p41, while JWH-030 increased Cd3g levels. JWH-210 (10 mg/kg, 3 days, i.p.) is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 </del>of <del style="font-weight: bold; text-decoration: none;">ICR mice in vivo</del>. <del style="font-weight: bold; text-decoration: none;">Users are expected to handle the compound in accordance with </del>all <del style="font-weight: bold; text-decoration: none;">applicable regulations and safety guidelines within their jurisdiction. It is important to note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use </del>in <del style="font-weight: bold; text-decoration: none;">controlled environments where precision is paramount.<br>Is JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 Legal? <br>To evaluate whether the changes </del>of <del style="font-weight: bold; text-decoration: none;">coordinative functions by CNS damages were due to </del>test <del style="font-weight: bold; text-decoration: none;">substances</del>, <del style="font-weight: bold; text-decoration: none;">rota</del>-<del style="font-weight: bold; text-decoration: none;">rod test was performed using Rota</del>-<del style="font-weight: bold; text-decoration: none;">rod apparatus </del>(<del style="font-weight: bold; text-decoration: none;">Daejong, Seoul, Korea</del>)<del style="font-weight: bold; text-decoration: none;">. The test apparatus for </del>the <del style="font-weight: bold; text-decoration: none;">locomotor activity test was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in </del>the <del style="font-weight: bold; text-decoration: none;">chamber. In both tests</del>, a <del style="font-weight: bold; text-decoration: none;">group of mice were treated with negative control (vehicle, 1 mg/kg, i</del>.<del style="font-weight: bold; text-decoration: none;">p.), positive control (methamphetamine, 1 mg/kg, i.p.), or one of </del>the <del style="font-weight: bold; text-decoration: none;">three doses </del>of <del style="font-weight: bold; text-decoration: none;">test substances (0.1</del>, <del style="font-weight: bold; text-decoration: none;">1</del>, <del style="font-weight: bold; text-decoration: none;">5 mg/kg</del>, <del style="font-weight: bold; text-decoration: none;">i</del>.<del style="font-weight: bold; text-decoration: none;">p.) once every other day for 10 day</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">High </ins>resolution mass spectrometry <ins style="font-weight: bold; text-decoration: none;">such as LC</ins>-<ins style="font-weight: bold; text-decoration: none;">QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS allows </ins>the <ins style="font-weight: bold; text-decoration: none;">detection and identification </ins>of a <ins style="font-weight: bold; text-decoration: none;">broad spectrum of </ins>recreational <ins style="font-weight: bold; text-decoration: none;">drugs</ins>, <ins style="font-weight: bold; text-decoration: none;">including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed </ins>on the <ins style="font-weight: bold; text-decoration: none;">urine of </ins>the <ins style="font-weight: bold; text-decoration: none;">patient. He confirmed drinking 750 ml energy drink without any further consumption </ins>of <ins style="font-weight: bold; text-decoration: none;">food and using an </ins>e-cigarette <ins style="font-weight: bold; text-decoration: none;">from Gaziantep, Turkey 10 seconds before the onset of his first symptoms</ins>. <ins style="font-weight: bold; text-decoration: none;">He usually smokes </ins>a <ins style="font-weight: bold; text-decoration: none;">pack </ins>of <ins style="font-weight: bold; text-decoration: none;">cigarettes a day </ins>and <ins style="font-weight: bold; text-decoration: none;">sometimes smokes e-cigarettes</ins>. <ins style="font-weight: bold; text-decoration: none;">Combined with non-specific, transient symptoms</ins>, <ins style="font-weight: bold; text-decoration: none;">clinical recognition </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRA intoxication is challenging </ins>.<br>Data <ins style="font-weight: bold; text-decoration: none;">availability </ins><br><ins style="font-weight: bold; text-decoration: none;">The intensity is plotted against </ins>the <ins style="font-weight: bold; text-decoration: none;">retention time for both chromatograms</ins>, <ins style="font-weight: bold; text-decoration: none;">demonstrating </ins>the [https://cannabinoidsrc4f-adb.com/ <ins style="font-weight: bold; text-decoration: none;">4F ADB</ins>] <ins style="font-weight: bold; text-decoration: none;">presence and elution profiles </ins>of <ins style="font-weight: bold; text-decoration: none;">nicotine </ins>and <ins style="font-weight: bold; text-decoration: none;">ADB-BUTINACA </ins>in the <ins style="font-weight: bold; text-decoration: none;">analysed vape liquid sample. LC-QTOF-MS Chromatograms </ins>of <ins style="font-weight: bold; text-decoration: none;">Nicotine </ins>(<ins style="font-weight: bold; text-decoration: none;">Top</ins>) <ins style="font-weight: bold; text-decoration: none;">and ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC</ins>-<ins style="font-weight: bold; text-decoration: none;">QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS analysis showed that the e</ins>-<ins style="font-weight: bold; text-decoration: none;">liquid contained nicotine </ins>and <ins style="font-weight: bold; text-decoration: none;">ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINACA </ins>(<ins style="font-weight: bold; text-decoration: none;">Fig. 1</ins>). <ins style="font-weight: bold; text-decoration: none;">Because </ins>the <ins style="font-weight: bold; text-decoration: none;">point-</ins>of-<ins style="font-weight: bold; text-decoration: none;">care DOA test is generally not able </ins>to <ins style="font-weight: bold; text-decoration: none;">detect synthetic recreational drug substances</ins>, the <ins style="font-weight: bold; text-decoration: none;">liquid of </ins>the <ins style="font-weight: bold; text-decoration: none;">e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarette </ins>was <ins style="font-weight: bold; text-decoration: none;">thereafter screened using liquid chromatography</ins>-<ins style="font-weight: bold; text-decoration: none;">quadrupole time</ins>-<ins style="font-weight: bold; text-decoration: none;">of</ins>-<ins style="font-weight: bold; text-decoration: none;">flight mass spectrometry (LC</ins>-<ins style="font-weight: bold; text-decoration: none;">QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS) on the Waters™ Xevo G3 QTOF MS system</ins>. <ins style="font-weight: bold; text-decoration: none;">After eating a light meal and drinking caffeinated sports drinks at </ins>the <ins style="font-weight: bold; text-decoration: none;">ER</ins>, the <ins style="font-weight: bold; text-decoration: none;">nausea complaints of the patient were reduced </ins>and the <ins style="font-weight: bold; text-decoration: none;">patient was discharged hom</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-</ins>of<ins style="font-weight: bold; text-decoration: none;">-care DOA tests. In this case, </ins>the <ins style="font-weight: bold; text-decoration: none;">point-of-care DOA urine screening </ins>was <ins style="font-weight: bold; text-decoration: none;">not able </ins>to <ins style="font-weight: bold; text-decoration: none;">detect </ins>the <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoid </ins>ADB-<ins style="font-weight: bold; text-decoration: none;">BUTINAC<br><br>Legal status <br>JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements</ins>. <ins style="font-weight: bold; text-decoration: none;">Researchers often require compounds that are consistent and dependable</ins>, and <ins style="font-weight: bold; text-decoration: none;">this product delivers on both fronts. Whether used in small</ins>-<ins style="font-weight: bold; text-decoration: none;">scale experiments or larger research projects, </ins>the compound <ins style="font-weight: bold; text-decoration: none;">maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency</ins>, and <ins style="font-weight: bold; text-decoration: none;">accuracy, making it suitable for controlled experimental environments</ins>. <ins style="font-weight: bold; text-decoration: none;">This study was supported by </ins>a <ins style="font-weight: bold; text-decoration: none;">grant (13181MFDS654) </ins>of the <ins style="font-weight: bold; text-decoration: none;">National Institute </ins>of <ins style="font-weight: bold; text-decoration: none;">Food </ins>and <ins style="font-weight: bold; text-decoration: none;">Drug Safety Evaluation</ins>, <ins style="font-weight: bold; text-decoration: none;">Ministry </ins>of <ins style="font-weight: bold; text-decoration: none;">Food </ins>and <ins style="font-weight: bold; text-decoration: none;">Drug Safety</ins>, <ins style="font-weight: bold; text-decoration: none;">Republic of Kore</ins><br><br><br>As <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally</ins>, <ins style="font-weight: bold; text-decoration: none;">clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset </ins>of <ins style="font-weight: bold; text-decoration: none;">his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was </ins>the <ins style="font-weight: bold; text-decoration: none;">only substance detected, while </ins>in <ins style="font-weight: bold; text-decoration: none;">seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br>5F-MDMB-PINACA </ins>(<ins style="font-weight: bold; text-decoration: none;">also known as 5F-ADB, 5F-ADB</ins>-PINACA<ins style="font-weight: bold; text-decoration: none;">)</ins>, MDMB-<ins style="font-weight: bold; text-decoration: none;">CHIMICA</ins>, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA <ins style="font-weight: bold; text-decoration: none;">(also known </ins>as <ins style="font-weight: bold; text-decoration: none;">FUB-AMB</ins>, <ins style="font-weight: bold; text-decoration: none;">MMB-FUBINACA</ins>) <ins style="font-weight: bold; text-decoration: none;">were tested for in vivo cannabinoid</ins>-like effects <ins style="font-weight: bold; text-decoration: none;">to assess their </ins>abuse liabilit<br><br><ins style="font-weight: bold; text-decoration: none;">As most </ins>of the <ins style="font-weight: bold; text-decoration: none;">urine samples obtained in this study were found </ins>to <ins style="font-weight: bold; text-decoration: none;">contain other SCBs’ metabolites and other drugs, </ins>the <ins style="font-weight: bold; text-decoration: none;">urinary profile of </ins>the <ins style="font-weight: bold; text-decoration: none;">three individual urine samples that encompass 4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA metabolites exclusively </ins>(<ins style="font-weight: bold; text-decoration: none;">Table 3</ins>) <ins style="font-weight: bold; text-decoration: none;">is worth considering when selecting a suitable urinary marke<br></ins><br><br><ins style="font-weight: bold; text-decoration: none;">Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography</ins>-<ins style="font-weight: bold; text-decoration: none;">mass spectrometry. The authors declare that they have no known competing financial interests </ins>or <ins style="font-weight: bold; text-decoration: none;">personal relationships that could have appeared to influence the work reported in this paper. Second</ins>, <ins style="font-weight: bold; text-decoration: none;">we could not 4F ADB retrieve </ins>further <ins style="font-weight: bold; text-decoration: none;">detailed information about the e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarette that was used by the patient such </ins>as <ins style="font-weight: bold; text-decoration: none;">the label or the region of origin. Whether </ins>a <ins style="font-weight: bold; text-decoration: none;">recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarette. Of these samples, 22 contained one or more SCRAs</ins>, <ins style="font-weight: bold; text-decoration: none;">THC was only detected in 11 samples</ins>, <ins style="font-weight: bold; text-decoration: none;">only one contained cannabidiol </ins>and <ins style="font-weight: bold; text-decoration: none;">6 contained </ins>a <ins style="font-weight: bold; text-decoration: none;">mixture of THC and cannabidiol</ins>. <ins style="font-weight: bold; text-decoration: none;">There is difficulty in finding the right information about the NPS</ins>, <ins style="font-weight: bold; text-decoration: none;">defining their potency and confirmation </ins>of <ins style="font-weight: bold; text-decoration: none;">their existence in e</ins>-<ins style="font-weight: bold; text-decoration: none;">liquids or urine samples</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Data availabili</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">LC-QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS represents </ins>a <ins style="font-weight: bold; text-decoration: none;">significant advancement </ins>in the <ins style="font-weight: bold; text-decoration: none;">field </ins>of <ins style="font-weight: bold; text-decoration: none;">drug detection</ins>, <ins style="font-weight: bold; text-decoration: none;">offering higher sensitivity</ins>, <ins style="font-weight: bold; text-decoration: none;">specificity</ins>, and <ins style="font-weight: bold; text-decoration: none;">a broader spectrum </ins>of <ins style="font-weight: bold; text-decoration: none;">detectable substances</ins>. <ins style="font-weight: bold; text-decoration: none;">Despite </ins>all <ins style="font-weight: bold; text-decoration: none;">negative results </ins>in <ins style="font-weight: bold; text-decoration: none;">the point</ins>-of<ins style="font-weight: bold; text-decoration: none;">-care </ins>test <ins style="font-weight: bold; text-decoration: none;">for recreational drugs</ins>, <ins style="font-weight: bold; text-decoration: none;">the liquid chromatography-quadrupole time</ins>-<ins style="font-weight: bold; text-decoration: none;">of</ins>-<ins style="font-weight: bold; text-decoration: none;">flight mass spectrometry </ins>(<ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS</ins>) <ins style="font-weight: bold; text-decoration: none;">analysis showed that </ins>the <ins style="font-weight: bold; text-decoration: none;">liquid of </ins>the <ins style="font-weight: bold; text-decoration: none;">e-cigarette contained ADB-BUTINACA</ins>, a <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoid</ins>. <ins style="font-weight: bold; text-decoration: none;">We report a 27-year-old man who was admitted to </ins>the <ins style="font-weight: bold; text-decoration: none;">emergency room because </ins>of <ins style="font-weight: bold; text-decoration: none;">sudden 4F ADB headache</ins>, <ins style="font-weight: bold; text-decoration: none;">nausea</ins>, <ins style="font-weight: bold; text-decoration: none;">vertigo</ins>, <ins style="font-weight: bold; text-decoration: none;">red eyes and palpitations</ins>. <ins style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=225184&oldid=prev DamonAngas210 at 09:43, 24 May 2026 2026-05-24T09:43:34Z

<p></p> <a href="https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=225184&oldid=225155">Show changes</a>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=225155&oldid=prev DamonAngas210 at 09:40, 24 May 2026 2026-05-24T09:40:14Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:40, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Acute kidney damage and even kidney failure have been reported following use of synthetic cannabinoids (Davidson, et al., 2017). One recent study has looked at other mechanisms of action in some of the older synthetic cannabinoids and reported </del>that <del style="font-weight: bold; text-decoration: none;">some produced varying amounts of activity at sites which are related to cardiotoxicity and heart disease (Wiley et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2016). It is not known whether the increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9-THC or whether these "super-strength" cannabinoids produce effects at other receptors. A major cause of concern is </del>that <del style="font-weight: bold; text-decoration: none;">some of the more recently seen synthetic cannabinoids </del>are <del style="font-weight: bold; text-decoration: none;">more likely to produce extremely toxic effects than the older synthetics (Tai </del>and <del style="font-weight: bold; text-decoration: none;">Fantegrossi</del>, <del style="font-weight: bold; text-decoration: none;">2017<br><br><br>Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times </del>and <del style="font-weight: bold; text-decoration: none;">dose ranges for the drug discrimination assay were selected based </del>on <del style="font-weight: bold; text-decoration: none;">the time of peak depression </del>in <del style="font-weight: bold; text-decoration: none;">the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al.</del>, <del style="font-weight: bold; text-decoration: none;">2014), whereas </del>the <del style="font-weight: bold; text-decoration: none;">potency of a recent set was 0</del>.<del style="font-weight: bold; text-decoration: none;">09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems </del>of <del style="font-weight: bold; text-decoration: none;">long-acting adverse effects </del>and <del style="font-weight: bold; text-decoration: none;">interactions with other drugs</del>. <del style="font-weight: bold; text-decoration: none;">The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems </del>to <del style="font-weight: bold; text-decoration: none;">be a trend of newer synthetic cannabinoids being more potent than earlier compound<br><br>5F-MDMB-PINACA (also known as 5F-ADB</del>, <del style="font-weight: bold; text-decoration: none;">5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA</del>, and <del style="font-weight: bold; text-decoration: none;">AMB-FUBINACA (also known as FUB-AMB</del>, <del style="font-weight: bold; text-decoration: none;">MMB-FUBINACA) were tested </del>for <del style="font-weight: bold; text-decoration: none;">in vivo cannabinoid-like effects to assess their abuse liabilit<br><br><br>Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 </del>. This <del style="font-weight: bold; text-decoration: none;">is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test </del>(<del style="font-weight: bold; text-decoration: none;">including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants</del>) <del style="font-weight: bold; text-decoration: none;">were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection </del>of <del style="font-weight: bold; text-decoration: none;">SCRA in samples taken from </del>the <del style="font-weight: bold; text-decoration: none;">patient.<br>Data availabili<br><br><br>Briefly, the FOB test was comprised </del>of <del style="font-weight: bold; text-decoration: none;">several behavioral changes including catalepsy, traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex, </del>and <del style="font-weight: bold; text-decoration: none;">death. The FOB test was performed using published procedures (Moser et al., 1989) with some modifications. However</del>, <del style="font-weight: bold; text-decoration: none;">because </del>of <del style="font-weight: bold; text-decoration: none;">their subjective properties, it is necessary to set up a more objective automated measurement to determine their neurotoxicity. However, there are only a couple of anecdotal reports suspecting the possibility of their neurotoxicity with no scientific evidence (Cohen et al., 2012; McGuinness </del>and <del style="font-weight: bold; text-decoration: none;">Newell, 2012; Harris and Brown, 2013; Hermanns et al., 2013<br><br>AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017)</del>, <del style="font-weight: bold; text-decoration: none;">which suggests that the range between behaviorally active and toxic doses </del>of <del style="font-weight: bold; text-decoration: none;">AMB-FUBINACA is narro</del><br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, <del style="font-weight: bold; text-decoration: none;"> [https://cannabinoidsrc4f-adb.com/ 5CL ADBA powder] </del>while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound </ins>that <ins style="font-weight: bold; text-decoration: none;">meets stringent requirements</ins>. <ins style="font-weight: bold; text-decoration: none;">Researchers often require compounds </ins>that are <ins style="font-weight: bold; text-decoration: none;">consistent </ins>and <ins style="font-weight: bold; text-decoration: none;">dependable</ins>, and <ins style="font-weight: bold; text-decoration: none;">this product delivers </ins>on <ins style="font-weight: bold; text-decoration: none;">both fronts. Whether used </ins>in <ins style="font-weight: bold; text-decoration: none;">small-scale experiments or larger research projects</ins>, the <ins style="font-weight: bold; text-decoration: none;">compound maintains its integrity under recommended storage conditions</ins>. <ins style="font-weight: bold; text-decoration: none;">This ensures ease </ins>of <ins style="font-weight: bold; text-decoration: none;">handling </ins>and <ins style="font-weight: bold; text-decoration: none;">precise measurement during laboratory use</ins>. <ins style="font-weight: bold; text-decoration: none;">Each batch undergoes detailed verification </ins>to <ins style="font-weight: bold; text-decoration: none;">ensure purity</ins>, <ins style="font-weight: bold; text-decoration: none;">consistency</ins>, and <ins style="font-weight: bold; text-decoration: none;">accuracy</ins>, <ins style="font-weight: bold; text-decoration: none;">making it suitable </ins>for <ins style="font-weight: bold; text-decoration: none;">controlled experimental environments</ins>. This <ins style="font-weight: bold; text-decoration: none;">study was supported by a grant </ins>(<ins style="font-weight: bold; text-decoration: none;">13181MFDS654</ins>) of the <ins style="font-weight: bold; text-decoration: none;">National Institute </ins>of <ins style="font-weight: bold; text-decoration: none;">Food </ins>and <ins style="font-weight: bold; text-decoration: none;">Drug Safety Evaluation</ins>, <ins style="font-weight: bold; text-decoration: none;">Ministry </ins>of <ins style="font-weight: bold; text-decoration: none;">Food </ins>and <ins style="font-weight: bold; text-decoration: none;">Drug Safety</ins>, <ins style="font-weight: bold; text-decoration: none;">Republic </ins>of <ins style="font-weight: bold; text-decoration: none;">Kore</ins><br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<ins style="font-weight: bold; text-decoration: none;"><br><br><br>In general, the locomotor depressant and discriminative stimulus effects [https://cannabinoidsrc4f-adb.com/ More Bonuses] have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval.<br>Michael B Gatch <br>Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH</ins><br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<ins style="font-weight: bold; text-decoration: none;"><br><br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the More Bonuses highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=225128&oldid=prev DamonAngas210 at 09:37, 24 May 2026 2026-05-24T09:37:40Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:37, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">In the present study</del>, <del style="font-weight: bold; text-decoration: none;">we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluation</del>. <del style="font-weight: bold; text-decoration: none;">Known for its stability and consistent composition</del>, <del style="font-weight: bold; text-decoration: none;">this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies</del>. <del style="font-weight: bold; text-decoration: none;">In this </del>study<del style="font-weight: bold; text-decoration: none;">, histopathological evaluation was performed to confirm the possibility </del>of <del style="font-weight: bold; text-decoration: none;">neurotoxicity </del>of the <del style="font-weight: bold; text-decoration: none;">tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study, we evaluated the neurotoxicity of two </del>synthetic cannabinoids <del style="font-weight: bold; text-decoration: none;">(JWH-081 </del>and <del style="font-weight: bold; text-decoration: none;">JWH-210) through observation </del>of <del style="font-weight: bold; text-decoration: none;">various behavioral changes </del>and <del style="font-weight: bold; text-decoration: none;">analysis of histopathological changes using experimental mice with various doses </del>(<del style="font-weight: bold; text-decoration: none;">0</del>.<del style="font-weight: bold; text-decoration: none;">1</del>, <del style="font-weight: bold; text-decoration: none;">1, 5 mg/kg</del>). <del style="font-weight: bold; text-decoration: none;">Selecting powder JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 demands careful evaluation </del>of <del style="font-weight: bold; text-decoration: none;">purity, legality, </del>and <del style="font-weight: bold; text-decoration: none;">supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity</del>, <del style="font-weight: bold; text-decoration: none;">and vendor complianc</del><br><br><br><del style="font-weight: bold; text-decoration: none;">Product ions detected at m</del>/<del style="font-weight: bold; text-decoration: none;">z 302, 217, and 145 (B2) confirmed that tert</del>-<del style="font-weight: bold; text-decoration: none;">leucine </del>and <del style="font-weight: bold; text-decoration: none;">indazole moieties remained unchanged, leading to </del>the <del style="font-weight: bold; text-decoration: none;">structure elucidation </del>of <del style="font-weight: bold; text-decoration: none;">a hydroxy-functional group at </del>the <del style="font-weight: bold; text-decoration: none;">4-position </del>of the <del style="font-weight: bold; text-decoration: none;">butyl side chain by oxidative defluorination</del>. <del style="font-weight: bold; text-decoration: none;">The product ion m</del>/<del style="font-weight: bold; text-decoration: none;">z 336 </del>(<del style="font-weight: bold; text-decoration: none;">loss of methyl ester moiety</del>) <del style="font-weight: bold; text-decoration: none;">further confirmed </del>the <del style="font-weight: bold; text-decoration: none;">presence </del>of <del style="font-weight: bold; text-decoration: none;">dihydroxylated metabolites</del>. <del style="font-weight: bold; text-decoration: none;">The precursor ion, m</del>/<del style="font-weight: bold; text-decoration: none;">z 364 </del>(<del style="font-weight: bold; text-decoration: none;">B14</del>, <del style="font-weight: bold; text-decoration: none;">B5/B6</del>) <del style="font-weight: bold; text-decoration: none;">had a loss </del>of <del style="font-weight: bold; text-decoration: none;">2 Da from m</del>/<del style="font-weight: bold; text-decoration: none;">z 366 indicated further dehydrogenation </del>of <del style="font-weight: bold; text-decoration: none;">the ester hydrolysis plus monohydroxylated metabolites</del>. The <del style="font-weight: bold; text-decoration: none;">presence </del>of the <del style="font-weight: bold; text-decoration: none;">product ion m/z 320</del>, <del style="font-weight: bold; text-decoration: none;">likely formed from </del>a <del style="font-weight: bold; text-decoration: none;">loss </del>of <del style="font-weight: bold; text-decoration: none;">carbon dioxide</del>, <del style="font-weight: bold; text-decoration: none;">indicated monohydroxylation at the tert-leucine in B8 (m/z 219)</del>, <del style="font-weight: bold; text-decoration: none;">butyl side chain in B9 (m/z 145) </del>and <del style="font-weight: bold; text-decoration: none;">indazole moiety in B13 (m/z 161)</del>. <del style="font-weight: bold; text-decoration: none;">The precursor ion, m/z 350 showed </del>a <del style="font-weight: bold; text-decoration: none;">loss </del>of <del style="font-weight: bold; text-decoration: none;">14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.</del><br><del style="font-weight: bold; text-decoration: none;">Fig. 2. </del><br><del style="font-weight: bold; text-decoration: none;">4F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">BINACA was hydrolysed via ester hydrolysis forming the 4F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">BINACA ester hydrolysis metabolite </del>(<del style="font-weight: bold; text-decoration: none;">B22</del>)<del style="font-weight: bold; text-decoration: none;">. Data obtained from </del>the <del style="font-weight: bold; text-decoration: none;">twenty urine </del>samples <del style="font-weight: bold; text-decoration: none;">were retrospectively analysed </del>and <del style="font-weight: bold; text-decoration: none;">processed using TraceFinder software based on the identification criteria </del>of <del style="font-weight: bold; text-decoration: none;">mass errors less than ± 5 ppm for full MS peaks </del>and <del style="font-weight: bold; text-decoration: none;">MS/MS peaks from </del>the <del style="font-weight: bold; text-decoration: none;">theoretical mass and matching </del>of <del style="font-weight: bold; text-decoration: none;">MS/MS spectra</del>. <del style="font-weight: bold; text-decoration: none;">The mixture was vortex-mixed </del>and <del style="font-weight: bold; text-decoration: none;">500 µL </del>of <del style="font-weight: bold; text-decoration: none;">this mixture and 500 µL </del>of <del style="font-weight: bold; text-decoration: none;">methanol were loaded onto </del>the <del style="font-weight: bold; text-decoration: none;">Clean Screen FASt® tube</del>. <del style="font-weight: bold; text-decoration: none;">After incubation</del>, the <del style="font-weight: bold; text-decoration: none;">mixture </del>was <del style="font-weight: bold; text-decoration: none;">cooled at room temperature</del>, and <del style="font-weight: bold; text-decoration: none;">150 µL of purified water </del>was <del style="font-weight: bold; text-decoration: none;">added</del>. <del style="font-weight: bold; text-decoration: none;">High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies</del>) <del style="font-weight: bold; text-decoration: none;">equipped </del>with <del style="font-weight: bold; text-decoration: none;">dual electrospray ionization (ESI) source operated in both positive and negative ion modes</del>, to determine <del style="font-weight: bold; text-decoration: none;">accurate masses </del>of the <del style="font-weight: bold; text-decoration: none;">metabolites. Chromatographic separation was performed on an Agilent 1290 LC system </del>with <del style="font-weight: bold; text-decoration: none;">a Poroshell 120 EC-C18 analytical column </del>(<del style="font-weight: bold; text-decoration: none;">2</del>.<del style="font-weight: bold; text-decoration: none;">7 μm</del>, <del style="font-weight: bold; text-decoration: none;">75 × 2.1 mm</del>; <del style="font-weight: bold; text-decoration: none;">Agilent Technologies</del>, <del style="font-weight: bold; text-decoration: none;">Santa Clara</del>, <del style="font-weight: bold; text-decoration: none;">CA</del>, <del style="font-weight: bold; text-decoration: none;">USA).</del><br><del style="font-weight: bold; text-decoration: none;">Fig</del>. <del style="font-weight: bold; text-decoration: none;">1</del>. <br><del style="font-weight: bold; text-decoration: none;">Monitoring metabolism of </del>synthetic cannabinoid <del style="font-weight: bold; text-decoration: none;">4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus</del>, [https://cannabinoidsrc4f-adb.com/ <del style="font-weight: bold; text-decoration: none;">4F ADB</del>] <del style="font-weight: bold; text-decoration: none;">liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL (0.37–4.1 ng/mL according to the reported cases) </del>of SCRA <del style="font-weight: bold; text-decoration: none;">and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol</del>, <del style="font-weight: bold; text-decoration: none;">because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30]</del>, <del style="font-weight: bold; text-decoration: none;">but no data on high doses of ethanol are available. Given that THC </del>and <del style="font-weight: bold; text-decoration: none;">ethanol act on the same receptors, data on their simultaneous use may yield important insights in this regard.</del><br><del style="font-weight: bold; text-decoration: none;">Fungus C</del>. <del style="font-weight: bold; text-decoration: none;">elegans </del><br><del style="font-weight: bold; text-decoration: none;">Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)</del>-<del style="font-weight: bold; text-decoration: none;">3</del>,<del style="font-weight: bold; text-decoration: none;">3</del>-<del style="font-weight: bold; text-decoration: none;">dimethylbutanoate (4F-MDMB-BINACA</del>, <del style="font-weight: bold; text-decoration: none;">4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA or 4F</del>-<del style="font-weight: bold; text-decoration: none;">ADB)</del>, <del style="font-weight: bold; text-decoration: none;">found in numerous SCB product seizures, has been reported by various law enforcement since 2018 . However, most </del>of <del style="font-weight: bold; text-decoration: none;">the SCBs are full agonists at CB1 and CB2 receptors</del>, <del style="font-weight: bold; text-decoration: none;">having </del>a <del style="font-weight: bold; text-decoration: none;">higher risk </del>of <del style="font-weight: bold; text-decoration: none;">undesirable side effects when compared </del>to <del style="font-weight: bold; text-decoration: none;">THC which is </del>a <del style="font-weight: bold; text-decoration: none;">partial agonist </del>. <del style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2), where they elicit their main effect<br><br>As previously mentioned, all </del>of the compounds tested in the present study <del style="font-weight: bold; text-decoration: none;">(MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act </del>as <del style="font-weight: bold; text-decoration: none;">agonists at CB1 receptors </del>(<del style="font-weight: bold; text-decoration: none;">Banister </del>et al., <del style="font-weight: bold; text-decoration: none;">2015, 2016; Gamage et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2018</del>)<del style="font-weight: bold; text-decoration: none;">, which suggests these compounds will produce Δ9-THC-like </del>effects<del style="font-weight: bold; text-decoration: none;">, including abuse liabilit</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Acute kidney damage and even kidney failure have been reported following use of synthetic cannabinoids (Davidson</ins>, <ins style="font-weight: bold; text-decoration: none;">et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2017)</ins>. <ins style="font-weight: bold; text-decoration: none;">One recent </ins>study <ins style="font-weight: bold; text-decoration: none;">has looked at other mechanisms </ins>of <ins style="font-weight: bold; text-decoration: none;">action in some </ins>of the <ins style="font-weight: bold; text-decoration: none;">older </ins>synthetic cannabinoids and <ins style="font-weight: bold; text-decoration: none;">reported that some produced varying amounts </ins>of <ins style="font-weight: bold; text-decoration: none;">activity at sites which are related to cardiotoxicity </ins>and <ins style="font-weight: bold; text-decoration: none;">heart disease </ins>(<ins style="font-weight: bold; text-decoration: none;">Wiley et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2016</ins>). <ins style="font-weight: bold; text-decoration: none;">It is not known whether the increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9-THC or whether these "super</ins>-<ins style="font-weight: bold; text-decoration: none;">strength" cannabinoids produce effects at other receptors. A major cause </ins>of <ins style="font-weight: bold; text-decoration: none;">concern is that some of the more recently seen synthetic cannabinoids are more likely to produce extremely toxic effects than the older synthetics (Tai </ins>and <ins style="font-weight: bold; text-decoration: none;">Fantegrossi</ins>, <ins style="font-weight: bold; text-decoration: none;">2017</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">Tremors were observed in mice 30 minutes following 1 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA in the present study. Pretreatment times </ins>and <ins style="font-weight: bold; text-decoration: none;">dose ranges for the drug discrimination assay were selected based on </ins>the <ins style="font-weight: bold; text-decoration: none;">time </ins>of <ins style="font-weight: bold; text-decoration: none;">peak depression in </ins>the <ins style="font-weight: bold; text-decoration: none;">locomotor activity assay in mice. Average potency </ins>of the <ins style="font-weight: bold; text-decoration: none;">discriminative stimulus effects of early compounds was 0.81±0</ins>.<ins style="font-weight: bold; text-decoration: none;">17 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg </ins>(<ins style="font-weight: bold; text-decoration: none;">Gatch et al., 2014</ins>)<ins style="font-weight: bold; text-decoration: none;">, whereas </ins>the <ins style="font-weight: bold; text-decoration: none;">potency </ins>of <ins style="font-weight: bold; text-decoration: none;">a recent set was 0</ins>.<ins style="font-weight: bold; text-decoration: none;">09±0.03 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg </ins>(<ins style="font-weight: bold; text-decoration: none;">Gatch et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2018</ins>)<ins style="font-weight: bold; text-decoration: none;">, and the potency </ins>of <ins style="font-weight: bold; text-decoration: none;">the current set is 0.05±0.01 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems </ins>of <ins style="font-weight: bold; text-decoration: none;">long-acting adverse effects and interactions with other drugs</ins>. The <ins style="font-weight: bold; text-decoration: none;">duration of action </ins>of the <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoids tested using the 8-h protocol have varied widely</ins>, <ins style="font-weight: bold; text-decoration: none;">with some producing </ins>a <ins style="font-weight: bold; text-decoration: none;">duration </ins>of <ins style="font-weight: bold; text-decoration: none;">action no longer than 1 h</ins>, <ins style="font-weight: bold; text-decoration: none;">others producing a duration of action between 1–2 h</ins>, and <ins style="font-weight: bold; text-decoration: none;">others lasting more than 2 h</ins>. <ins style="font-weight: bold; text-decoration: none;">There seems to be </ins>a <ins style="font-weight: bold; text-decoration: none;">trend </ins>of <ins style="font-weight: bold; text-decoration: none;">newer synthetic cannabinoids being more potent than earlier compound</ins><br><br><ins style="font-weight: bold; text-decoration: none;">5F</ins>-MDMB-<ins style="font-weight: bold; text-decoration: none;">PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">CHIMICA, </ins>MDMB-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, ADB-FUBINACA, and AMB-FUBINACA </ins>(<ins style="font-weight: bold; text-decoration: none;">also known as FUB-AMB, MMB-FUBINACA</ins>) <ins style="font-weight: bold; text-decoration: none;">were tested for in vivo cannabinoid-like effects to assess their abuse liabilit<br><br><br>Moreover, a study conducted in </ins>the <ins style="font-weight: bold; text-decoration: none;">United Kingdom investigated components of e-liquids in 112 </ins>samples <ins style="font-weight: bold; text-decoration: none;">originating from prisoners, teenagers </ins>and <ins style="font-weight: bold; text-decoration: none;">test purchases </ins>of <ins style="font-weight: bold; text-decoration: none;">commercially available e-cigarettes taken between 2014 </ins>and <ins style="font-weight: bold; text-decoration: none;">2021 . This is the first case report that describes </ins>the <ins style="font-weight: bold; text-decoration: none;">toxicological symptoms </ins>of <ins style="font-weight: bold; text-decoration: none;">vaping ADB-BUTINACA</ins>. <ins style="font-weight: bold; text-decoration: none;">Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes </ins>and <ins style="font-weight: bold; text-decoration: none;">were all negative. We report a case of an involuntary intoxication </ins>of <ins style="font-weight: bold; text-decoration: none;">the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRA in samples taken from </ins>the <ins style="font-weight: bold; text-decoration: none;">patient</ins>.<ins style="font-weight: bold; text-decoration: none;"><br>Data availabili<br><br><br>Briefly</ins>, the <ins style="font-weight: bold; text-decoration: none;">FOB test </ins>was <ins style="font-weight: bold; text-decoration: none;">comprised of several behavioral changes including catalepsy, traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex</ins>, and <ins style="font-weight: bold; text-decoration: none;">death. The FOB test </ins>was <ins style="font-weight: bold; text-decoration: none;">performed using published procedures (Moser et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 1989</ins>) with <ins style="font-weight: bold; text-decoration: none;">some modifications. However, because of their subjective properties</ins>, <ins style="font-weight: bold; text-decoration: none;">it is necessary to set up a more objective automated measurement </ins>to determine <ins style="font-weight: bold; text-decoration: none;">their neurotoxicity. However, there are only a couple </ins>of <ins style="font-weight: bold; text-decoration: none;">anecdotal reports suspecting </ins>the <ins style="font-weight: bold; text-decoration: none;">possibility of their neurotoxicity </ins>with <ins style="font-weight: bold; text-decoration: none;">no scientific evidence </ins>(<ins style="font-weight: bold; text-decoration: none;">Cohen et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2012</ins>; <ins style="font-weight: bold; text-decoration: none;">McGuinness and Newell</ins>, <ins style="font-weight: bold; text-decoration: none;">2012; Harris and Brown</ins>, <ins style="font-weight: bold; text-decoration: none;">2013; Hermanns et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2013<br></ins><br><ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2017; Hamilton et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narro</ins><br><ins style="font-weight: bold; text-decoration: none;"><br><br>As </ins>synthetic cannabinoid <ins style="font-weight: bold; text-decoration: none;">receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINACA was the only substance detected</ins>, <ins style="font-weight: bold; text-decoration: none;"> </ins>[https://cannabinoidsrc4f-adb.com/ <ins style="font-weight: bold; text-decoration: none;">5CL ADBA powder</ins>] <ins style="font-weight: bold; text-decoration: none;">while in seven other substances </ins>of <ins style="font-weight: bold; text-decoration: none;">misuse were also detected including other </ins>SCRA, <ins style="font-weight: bold; text-decoration: none;">opioids</ins>, <ins style="font-weight: bold; text-decoration: none;">benzodiazepines cocaine </ins>and <ins style="font-weight: bold; text-decoration: none;">pregabali<br></ins><br><ins style="font-weight: bold; text-decoration: none;">4</ins>. <ins style="font-weight: bold; text-decoration: none;">Drugs </ins><br><ins style="font-weight: bold; text-decoration: none;">Short</ins>-<ins style="font-weight: bold; text-decoration: none;">onset</ins>, <ins style="font-weight: bold; text-decoration: none;">short</ins>-<ins style="font-weight: bold; text-decoration: none;">acting compounds have a greater abuse liability</ins>, <ins style="font-weight: bold; text-decoration: none;">and long</ins>-<ins style="font-weight: bold; text-decoration: none;">acting compounds pose problems of long</ins>-<ins style="font-weight: bold; text-decoration: none;">acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8</ins>-<ins style="font-weight: bold; text-decoration: none;">h protocol have varied widely</ins>, <ins style="font-weight: bold; text-decoration: none;">with some producing a duration </ins>of <ins style="font-weight: bold; text-decoration: none;">action no longer than 1 h</ins>, <ins style="font-weight: bold; text-decoration: none;">others producing </ins>a <ins style="font-weight: bold; text-decoration: none;">duration </ins>of <ins style="font-weight: bold; text-decoration: none;">action between 1–2 h, and others lasting more than 2 h. There seems </ins>to <ins style="font-weight: bold; text-decoration: none;">be </ins>a <ins style="font-weight: bold; text-decoration: none;">trend of newer synthetic cannabinoids being more potent than earlier compounds</ins>. <ins style="font-weight: bold; text-decoration: none;">All </ins>of the compounds tested in the present study <ins style="font-weight: bold; text-decoration: none;">depressed locomotor activity </ins>as <ins style="font-weight: bold; text-decoration: none;">is typical for other synthetic cannabinoids </ins>(<ins style="font-weight: bold; text-decoration: none;">see review by Wiley </ins>et al., <ins style="font-weight: bold; text-decoration: none;">2017)</ins>. <ins style="font-weight: bold; text-decoration: none;">Average horizontal activity counts/10 min as a function of time (10 min bins</ins>) <ins style="font-weight: bold; text-decoration: none;">and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant </ins>effects <ins style="font-weight: bold; text-decoration: none;">were observed between 0–30 min.<br>Michael B Gat</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=211224&oldid=prev DamonAngas210 at 12:17, 22 May 2026 2026-05-22T12:17:36Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 12:17, 22 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Briefly</del>, <del style="font-weight: bold; text-decoration: none;">the </del>FOB test <del style="font-weight: bold; text-decoration: none;">was comprised of several </del>behavioral <del style="font-weight: bold; text-decoration: none;">changes including catalepsy</del>, <del style="font-weight: bold; text-decoration: none;">traction</del>, <del style="font-weight: bold; text-decoration: none;">tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex</del>, and <del style="font-weight: bold; text-decoration: none;">death. The FOB </del>test <del style="font-weight: bold; text-decoration: none;">was performed using published procedures (Moser et al</del>., <del style="font-weight: bold; text-decoration: none;">1989) with some modifications</del>. <del style="font-weight: bold; text-decoration: none;">However</del>, <del style="font-weight: bold; text-decoration: none;">because </del>of <del style="font-weight: bold; text-decoration: none;">their subjective properties, it is necessary to set up a more objective automated measurement to determine their </del>neurotoxicity. <del style="font-weight: bold; text-decoration: none;">However</del>, <del style="font-weight: bold; text-decoration: none;">there are only a couple </del>of <del style="font-weight: bold; text-decoration: none;">anecdotal reports suspecting the possibility </del>of <del style="font-weight: bold; text-decoration: none;">their neurotoxicity </del>with <del style="font-weight: bold; text-decoration: none;">no scientific evidence </del>(<del style="font-weight: bold; text-decoration: none;">Cohen et al</del>., <del style="font-weight: bold; text-decoration: none;">2012; McGuinness and Newell</del>, <del style="font-weight: bold; text-decoration: none;">2012; Harris </del>and <del style="font-weight: bold; text-decoration: none;">Brown</del>, <del style="font-weight: bold; text-decoration: none;">2013; Hermanns et al.</del>, <del style="font-weight: bold; text-decoration: none;">2013</del><br><br><br><del style="font-weight: bold; text-decoration: none;">Test 2 was performed everyday for 5 days after consecutive administration of the substances</del>, <del style="font-weight: bold; text-decoration: none;">including negative </del>(<del style="font-weight: bold; text-decoration: none;">vehicle</del>) and <del style="font-weight: bold; text-decoration: none;">positive </del>(<del style="font-weight: bold; text-decoration: none;">methamphetamine</del>) <del style="font-weight: bold; text-decoration: none;">controls</del>. <del style="font-weight: bold; text-decoration: none;">After the last administration</del>, the <del style="font-weight: bold; text-decoration: none;">first trial was performed</del>. <del style="font-weight: bold; text-decoration: none;">Morris water maze test was performed to evaluate the changes of learning and memory function through administration </del>of the <del style="font-weight: bold; text-decoration: none;">test substances. Generally</del>, <del style="font-weight: bold; text-decoration: none;">neurotoxicity </del>of <del style="font-weight: bold; text-decoration: none;">a substance is evaluated by animal behavioral aspects</del>, <del style="font-weight: bold; text-decoration: none;">i.e. functional observation battery </del>(<del style="font-weight: bold; text-decoration: none;">FOB</del>) <del style="font-weight: bold; text-decoration: none;">tests </del>(<del style="font-weight: bold; text-decoration: none;">O’Callaghan et al., 2014</del>). <del style="font-weight: bold; text-decoration: none;">Our results suggest that JWH-081 and JWH-210 may 4F ADB be neurotoxic substances through changing neuronal cell damages</del>, <del style="font-weight: bold; text-decoration: none;">especially in </del>the <del style="font-weight: bold; text-decoration: none;">core shell part </del>of <del style="font-weight: bold; text-decoration: none;">nucleus accumbens</del>.<br><del style="font-weight: bold; text-decoration: none;">About Powder JWH-</del>2<del style="font-weight: bold; text-decoration: none;"><br><br>4</del>. <del style="font-weight: bold; text-decoration: none;">Drugs </del><br><del style="font-weight: bold; text-decoration: none;">In general, </del>the <del style="font-weight: bold; text-decoration: none;">locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 (Gatch et al., 2016), and 5F</del>-<del style="font-weight: bold; text-decoration: none;">AMB produced sustained vocalization and convulsions in rats </del>(<del style="font-weight: bold; text-decoration: none;">Gatch et al., 2018</del>). <del style="font-weight: bold; text-decoration: none;">All of </del>the <del style="font-weight: bold; text-decoration: none;">synthetic cannabinoids tested in </del>the <del style="font-weight: bold; text-decoration: none;">present study fully substituted </del>for the <del style="font-weight: bold; text-decoration: none;">discriminative stimulus effects </del>of <del style="font-weight: bold; text-decoration: none;">Δ9-THC</del>. <del style="font-weight: bold; text-decoration: none;">Subsequently, a one-way analysis of variance </del>was <del style="font-weight: bold; text-decoration: none;">conducted on horizontal activity counts for the 30</del>-<del style="font-weight: bold; text-decoration: none;">min period </del>of <del style="font-weight: bold; text-decoration: none;">maximal effect, </del>and <del style="font-weight: bold; text-decoration: none;">planned comparisons </del>were <del style="font-weight: bold; text-decoration: none;">conducted for each dose against </del>the <del style="font-weight: bold; text-decoration: none;">vehicle control using single degree-</del>of-<del style="font-weight: bold; text-decoration: none;">freedom F tests. A two</del>-<del style="font-weight: bold; text-decoration: none;">way analysis of variance, </del>with <del style="font-weight: bold; text-decoration: none;">dose as a between groups factor </del>and <del style="font-weight: bold; text-decoration: none;">time as a within subject factor</del>, was <del style="font-weight: bold; text-decoration: none;">conducted </del>on <del style="font-weight: bold; text-decoration: none;">horizontal activity counts/10 min interval</del>. <del style="font-weight: bold; text-decoration: none;">Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect</del>. <del style="font-weight: bold; text-decoration: none;">Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor</del>.<br><del style="font-weight: bold; text-decoration: none;">Michael B Gatch </del><br><del style="font-weight: bold; text-decoration: none;">Substantial depressant effects were observed within the first 10 min</del>, and <del style="font-weight: bold; text-decoration: none;">maximal depression was observed between 0–30 min following administration</del>. <del style="font-weight: bold; text-decoration: none;">Tremors were observed 30 minutes following </del>1 <del style="font-weight: bold; text-decoration: none;">mg</del>/<del style="font-weight: bold; text-decoration: none;">kg AMB-FUBINACA in 3 </del>of <del style="font-weight: bold; text-decoration: none;">8 mice (data not shown)</del>. <del style="font-weight: bold; text-decoration: none;">Substantial depressant effects were observed within </del>the <del style="font-weight: bold; text-decoration: none;">first 10 min</del>, and <del style="font-weight: bold; text-decoration: none;">maximal depression was observed </del>between <del style="font-weight: bold; text-decoration: none;">10–40 min </del>and <del style="font-weight: bold; text-decoration: none;">lasted up to 2</del>.<del style="font-weight: bold; text-decoration: none;">5 to 3 h at </del>the <del style="font-weight: bold; text-decoration: none;">4F ADB highest dose tested (0.5 mg/kg)</del>.<br><del style="font-weight: bold; text-decoration: none;">Figure 1</del>. <br><del style="font-weight: bold; text-decoration: none;">There is indication that at least some of the first</del>-<del style="font-weight: bold; text-decoration: none;">generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </del>(<del style="font-weight: bold; text-decoration: none;">Wiley et al., 2016</del>), <del style="font-weight: bold; text-decoration: none;">and a compound from the present study</del>, <del style="font-weight: bold; text-decoration: none;">5F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">PINACA</del>, <del style="font-weight: bold; text-decoration: none;">was </del>found <del style="font-weight: bold; text-decoration: none;">to activate midbrain dopamine neurons</del>, <del style="font-weight: bold; text-decoration: none;">but not serotonin neurons (Asaoka et al</del>., <del style="font-weight: bold; text-decoration: none;">2016</del>)<del style="font-weight: bold; text-decoration: none;">. </del>As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse <del style="font-weight: bold; text-decoration: none;">liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.<br>Michael B Gat<br><br><br>In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to 4F ADB quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.<br>Key Features and Specifications to Evaluate <br>In case of cannabis or Δ9-tetrahydrocannabinol, there are many [https://cannabinoidsrc4f-adb.com/ 4F ADB] previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998). After administering test substances once every other day for 10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day, and the first trial was performed 2 h after the last administration.<br>How to Choose Powder JWH-210 <br>When learning how to choose powder JWH-210, the most critical factor is verifying high chemical purity (≥98%) from a reputable supplier with independent lab testing. We also demonstrated that JWH-210 administration resulted in the decrease of expression levels of T-cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41, while JWH-030 increased Cd3g levels. JWH-210 (10 mg/kg, 3 days, i.p.) is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 of ICR mice in vivo. Users are expected to handle the compound in accordance with all applicable regulations and safety guidelines within their jurisdiction. It is important to note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramount.<br>Is JWH-210 Legal? <br>A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively. After the first injection, 6 mice of the positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">In the present study</ins>, <ins style="font-weight: bold; text-decoration: none;">we performed various methods based on animal behavioral testing including </ins>FOB test <ins style="font-weight: bold; text-decoration: none;">for general </ins>behavioral <ins style="font-weight: bold; text-decoration: none;">observation</ins>, <ins style="font-weight: bold; text-decoration: none;">rotarod test</ins>, <ins style="font-weight: bold; text-decoration: none;">locomotor activity test for motor function evaluation</ins>, and <ins style="font-weight: bold; text-decoration: none;">water-maze </ins>test <ins style="font-weight: bold; text-decoration: none;">for learning/memory evaluation</ins>. <ins style="font-weight: bold; text-decoration: none;">Known for its stability and consistent composition</ins>, <ins style="font-weight: bold; text-decoration: none;">this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies</ins>. <ins style="font-weight: bold; text-decoration: none;">In this study</ins>, <ins style="font-weight: bold; text-decoration: none;">histopathological evaluation was performed to confirm the possibility </ins>of neurotoxicity <ins style="font-weight: bold; text-decoration: none;">of the tested substances by hematoxylin and eosin staining method from collected brain samples</ins>. <ins style="font-weight: bold; text-decoration: none;">In the present study</ins>, <ins style="font-weight: bold; text-decoration: none;">we evaluated the neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation </ins>of <ins style="font-weight: bold; text-decoration: none;">various behavioral changes and analysis </ins>of <ins style="font-weight: bold; text-decoration: none;">histopathological changes using experimental mice </ins>with <ins style="font-weight: bold; text-decoration: none;">various doses </ins>(<ins style="font-weight: bold; text-decoration: none;">0.1, 1, 5 mg/kg)</ins>. <ins style="font-weight: bold; text-decoration: none;">Selecting powder JWH-210 demands careful evaluation of purity</ins>, <ins style="font-weight: bold; text-decoration: none;">legality</ins>, and <ins style="font-weight: bold; text-decoration: none;">supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity</ins>, <ins style="font-weight: bold; text-decoration: none;">purity</ins>, <ins style="font-weight: bold; text-decoration: none;">and vendor complianc</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">Product ions detected at m/z 302, 217</ins>, <ins style="font-weight: bold; text-decoration: none;">and 145 </ins>(<ins style="font-weight: bold; text-decoration: none;">B2</ins>) <ins style="font-weight: bold; text-decoration: none;">confirmed that tert-leucine </ins>and <ins style="font-weight: bold; text-decoration: none;">indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 </ins>(<ins style="font-weight: bold; text-decoration: none;">loss of methyl ester moiety</ins>) <ins style="font-weight: bold; text-decoration: none;">further confirmed the presence of dihydroxylated metabolites</ins>. <ins style="font-weight: bold; text-decoration: none;">The precursor ion, m/z 364 (B14</ins>, <ins style="font-weight: bold; text-decoration: none;">B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of </ins>the <ins style="font-weight: bold; text-decoration: none;">ester hydrolysis plus monohydroxylated metabolites</ins>. <ins style="font-weight: bold; text-decoration: none;">The presence </ins>of the <ins style="font-weight: bold; text-decoration: none;">product ion m/z 320</ins>, <ins style="font-weight: bold; text-decoration: none;">likely formed from a loss </ins>of <ins style="font-weight: bold; text-decoration: none;">carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219)</ins>, <ins style="font-weight: bold; text-decoration: none;">butyl side chain in B9 </ins>(<ins style="font-weight: bold; text-decoration: none;">m/z 145</ins>) <ins style="font-weight: bold; text-decoration: none;">and indazole moiety in B13 </ins>(<ins style="font-weight: bold; text-decoration: none;">m/z 161</ins>). <ins style="font-weight: bold; text-decoration: none;">The precursor ion</ins>, <ins style="font-weight: bold; text-decoration: none;">m/z 350 showed a loss of 14 Da explaining </ins>the <ins style="font-weight: bold; text-decoration: none;">hydrolysis </ins>of <ins style="font-weight: bold; text-decoration: none;">methyl ester from 4F-MDMB-BINACA</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Fig. </ins>2. <br><ins style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming </ins>the <ins style="font-weight: bold; text-decoration: none;">4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA ester hydrolysis metabolite </ins>(<ins style="font-weight: bold; text-decoration: none;">B22</ins>). <ins style="font-weight: bold; text-decoration: none;">Data obtained from </ins>the <ins style="font-weight: bold; text-decoration: none;">twenty urine samples were retrospectively analysed and processed using TraceFinder software based on </ins>the <ins style="font-weight: bold; text-decoration: none;">identification criteria of mass errors less than ± 5 ppm </ins>for <ins style="font-weight: bold; text-decoration: none;">full MS peaks and MS/MS peaks from </ins>the <ins style="font-weight: bold; text-decoration: none;">theoretical mass and matching </ins>of <ins style="font-weight: bold; text-decoration: none;">MS/MS spectra</ins>. <ins style="font-weight: bold; text-decoration: none;">The mixture </ins>was <ins style="font-weight: bold; text-decoration: none;">vortex</ins>-<ins style="font-weight: bold; text-decoration: none;">mixed and 500 µL </ins>of <ins style="font-weight: bold; text-decoration: none;">this mixture </ins>and <ins style="font-weight: bold; text-decoration: none;">500 µL of methanol </ins>were <ins style="font-weight: bold; text-decoration: none;">loaded onto the Clean Screen FASt® tube. After incubation, </ins>the <ins style="font-weight: bold; text-decoration: none;">mixture was cooled at room temperature, and 150 µL </ins>of <ins style="font-weight: bold; text-decoration: none;">purified water was added. High</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped </ins>with <ins style="font-weight: bold; text-decoration: none;">dual electrospray ionization (ESI) source operated in both positive </ins>and <ins style="font-weight: bold; text-decoration: none;">negative ion modes</ins>, <ins style="font-weight: bold; text-decoration: none;">to determine accurate masses of the metabolites. Chromatographic separation </ins>was <ins style="font-weight: bold; text-decoration: none;">performed </ins>on <ins style="font-weight: bold; text-decoration: none;">an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column (2</ins>.<ins style="font-weight: bold; text-decoration: none;">7 μm, 75 × 2</ins>.<ins style="font-weight: bold; text-decoration: none;">1 mm; Agilent Technologies, Santa Clara, CA, USA)</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Fig. 1. </ins><br><ins style="font-weight: bold; text-decoration: none;">Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus</ins>, <ins style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f-adb.com/ 4F ADB] liver microsomes </ins>and <ins style="font-weight: bold; text-decoration: none;">confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL (0.37–4</ins>.1 <ins style="font-weight: bold; text-decoration: none;">ng/mL according to the reported cases) of SCRA and 1.5–2.5 g</ins>/<ins style="font-weight: bold; text-decoration: none;">L </ins>of <ins style="font-weight: bold; text-decoration: none;">ethanol</ins>. <ins style="font-weight: bold; text-decoration: none;">The reported cases and reviews of </ins>the <ins style="font-weight: bold; text-decoration: none;">scientific literature suggest a possible synergistic effect between SCRAs and ethanol</ins>, <ins style="font-weight: bold; text-decoration: none;">because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis </ins>and <ins style="font-weight: bold; text-decoration: none;">acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect </ins>between <ins style="font-weight: bold; text-decoration: none;">THC </ins>and <ins style="font-weight: bold; text-decoration: none;">ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available</ins>. <ins style="font-weight: bold; text-decoration: none;">Given that THC and ethanol act on </ins>the <ins style="font-weight: bold; text-decoration: none;">same receptors, data on their simultaneous use may yield important insights in this regard</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Fungus C</ins>. <ins style="font-weight: bold; text-decoration: none;">elegans </ins><br><ins style="font-weight: bold; text-decoration: none;">Methyl (2S)-2-([1</ins>-(<ins style="font-weight: bold; text-decoration: none;">4-fluorobutyl)-1H-indazole-3-carbonyl]amino</ins>)<ins style="font-weight: bold; text-decoration: none;">-3</ins>,<ins style="font-weight: bold; text-decoration: none;">3-dimethylbutanoate (4F-MDMB-BINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">4F</ins>-MDMB-<ins style="font-weight: bold; text-decoration: none;">BUTINACA or 4F-ADB)</ins>, found <ins style="font-weight: bold; text-decoration: none;">in numerous SCB product seizures</ins>, <ins style="font-weight: bold; text-decoration: none;">has been reported by various law enforcement since 2018 </ins>. <ins style="font-weight: bold; text-decoration: none;">However</ins>, <ins style="font-weight: bold; text-decoration: none;">most of the SCBs are full agonists at CB1 and CB2 receptors, having a higher risk of undesirable side effects when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2</ins>)<ins style="font-weight: bold; text-decoration: none;">, where they elicit their main effect<br><br></ins>As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse <ins style="font-weight: bold; text-decoration: none;">liabilit</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=211212&oldid=prev DamonAngas210 at 12:13, 22 May 2026 2026-05-22T12:13:55Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 12:13, 22 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014<br><br>Legal status <br></del>Briefly, the FOB test was comprised of several behavioral changes including catalepsy, traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex, and death. The FOB test was performed using published procedures (Moser et al., 1989) with some modifications. However, because of their subjective properties, it is necessary to set up a more objective automated measurement to determine their neurotoxicity. However, there are only a couple of anecdotal reports suspecting the possibility of their neurotoxicity with no scientific evidence (Cohen et al., 2012; McGuinness and Newell, 2012; Harris and Brown, 2013; Hermanns et al., 2013<br><br><del style="font-weight: bold; text-decoration: none;">Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans </del><br><del style="font-weight: bold; text-decoration: none;">The % peak area abundance ratio </del>of <del style="font-weight: bold; text-decoration: none;">metabolites detected in </del>the <del style="font-weight: bold; text-decoration: none;">urine samples are often affected by numerous factors such as drug intake behaviour </del>(<del style="font-weight: bold; text-decoration: none;">intake route, amount of drug </del>and <del style="font-weight: bold; text-decoration: none;">intake frequency</del>), <del style="font-weight: bold; text-decoration: none;">time from last drug intake </del>and <del style="font-weight: bold; text-decoration: none;">metabolic stability</del>. <del style="font-weight: bold; text-decoration: none;">This indicated that the phase I metabolism </del>of <del style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA are unlikely to be affected significantly </del>by <del style="font-weight: bold; text-decoration: none;">polydrug intake</del>. <del style="font-weight: bold; text-decoration: none;">Oxidative defluorination with subsequent butanoic acid formation </del>(<del style="font-weight: bold; text-decoration: none;">B17</del>) <del style="font-weight: bold; text-decoration: none;">metabolite</del>, <del style="font-weight: bold; text-decoration: none;">the second major metabolite after monohydroxylation in the C</del>. <del style="font-weight: bold; text-decoration: none;">Ester hydrolysis with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA </del>and <del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">4en-PINACA [39</del>, <del style="font-weight: bold; text-decoration: none;">40]. Similar to the </del>in<del style="font-weight: bold; text-decoration: none;">-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models, consistent with </del>the <del style="font-weight: bold; text-decoration: none;">known hydrolytic activity </del>of <del style="font-weight: bold; text-decoration: none;">CES reported</del><br><br><br><del style="font-weight: bold; text-decoration: none;">High resolution mass spectrometry such as LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS allows the detection </del>and <del style="font-weight: bold; text-decoration: none;">identification </del>of <del style="font-weight: bold; text-decoration: none;">a broad spectrum </del>of <del style="font-weight: bold; text-decoration: none;">recreational drugs</del>, <del style="font-weight: bold; text-decoration: none;">including new psychoactive substances. A point</del>-of<del style="font-weight: bold; text-decoration: none;">-care drugs of abuse (DOA) test </del>was <del style="font-weight: bold; text-decoration: none;">initially performed </del>on the <del style="font-weight: bold; text-decoration: none;">urine </del>of the <del style="font-weight: bold; text-decoration: none;">patient. He confirmed drinking 750 ml energy drink without any further consumption of food and </del>using <del style="font-weight: bold; text-decoration: none;">an e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette from Gaziantep, Turkey 10 seconds before the onset </del>of <del style="font-weight: bold; text-decoration: none;">his first symptoms</del>. <del style="font-weight: bold; text-decoration: none;">He usually smokes a pack </del>of <del style="font-weight: bold; text-decoration: none;">cigarettes </del>a <del style="font-weight: bold; text-decoration: none;">day </del>and <del style="font-weight: bold; text-decoration: none;">sometimes smokes e-cigarettes</del>. <del style="font-weight: bold; text-decoration: none;">Combined with non</del>-<del style="font-weight: bold; text-decoration: none;">specific, transient symptoms, clinical recognition </del>of <del style="font-weight: bold; text-decoration: none;">SCRA intoxication is challenging </del>.<br><del style="font-weight: bold; text-decoration: none;">Data availability </del><br><del style="font-weight: bold; text-decoration: none;">The intensity is plotted against </del>the <del style="font-weight: bold; text-decoration: none;">retention time for both chromatograms</del>, <del style="font-weight: bold; text-decoration: none;">demonstrating the [https://cannabinoidsrc4f-adb</del>.<del style="font-weight: bold; text-decoration: none;">com</del>/ <del style="font-weight: bold; text-decoration: none;">4F ADB] presence and elution profiles of nicotine and ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA </del>in <del style="font-weight: bold; text-decoration: none;">the analysed vape liquid sample. LC-QTOF-MS Chromatograms </del>of <del style="font-weight: bold; text-decoration: none;">Nicotine </del>(<del style="font-weight: bold; text-decoration: none;">Top</del>) and ADB<del style="font-weight: bold; text-decoration: none;">-BUTINACA </del>(<del style="font-weight: bold; text-decoration: none;">Bottom</del>) <del style="font-weight: bold; text-decoration: none;">in the Vape Liquid used by the patient</del>. <del style="font-weight: bold; text-decoration: none;">The LC-QTOF-MS analysis showed </del>that the <del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">liquid contained nicotine </del>and <del style="font-weight: bold; text-decoration: none;">ADB-BUTINACA </del>(<del style="font-weight: bold; text-decoration: none;">Fig</del>. <del style="font-weight: bold; text-decoration: none;">1</del>)<del style="font-weight: bold; text-decoration: none;">. Because </del>the <del style="font-weight: bold; text-decoration: none;">point</del>-<del style="font-weight: bold; text-decoration: none;">of</del>-<del style="font-weight: bold; text-decoration: none;">care DOA test is generally </del>not <del style="font-weight: bold; text-decoration: none;">able to detect synthetic recreational drug substances</del>, the <del style="font-weight: bold; text-decoration: none;">liquid of </del>the <del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette was thereafter screened using liquid chromatography</del>-<del style="font-weight: bold; text-decoration: none;">quadrupole time</del>-<del style="font-weight: bold; text-decoration: none;">of</del>-<del style="font-weight: bold; text-decoration: none;">flight mass spectrometry </del>(<del style="font-weight: bold; text-decoration: none;">LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS) on the Waters™ Xevo G3 QTOF MS system</del>. <del style="font-weight: bold; text-decoration: none;">After eating a light meal and drinking caffeinated sports drinks at </del>the <del style="font-weight: bold; text-decoration: none;">ER</del>, the <del style="font-weight: bold; text-decoration: none;">nausea complaints of </del>the <del style="font-weight: bold; text-decoration: none;">patient were reduced and </del>the <del style="font-weight: bold; text-decoration: none;">patient was discharged hom</del><br><br><br><del style="font-weight: bold; text-decoration: none;">LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS represents a significant advancement in the field of drug detection, offering higher sensitivity</del>, <del style="font-weight: bold; text-decoration: none;">specificity</del>, and a <del style="font-weight: bold; text-decoration: none;">broader spectrum of detectable substances</del>. <del style="font-weight: bold; text-decoration: none;">Despite all negative results in the point-of-care test for recreational drugs</del>, <del style="font-weight: bold; text-decoration: none;">the liquid chromatography-quadrupole time-</del>of<del style="font-weight: bold; text-decoration: none;">-flight mass spectrometry (LC-QTOF-MS) analysis showed that </del>the <del style="font-weight: bold; text-decoration: none;">liquid of the e-cigarette contained ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA, a synthetic cannabinoid</del>. <del style="font-weight: bold; text-decoration: none;">We report a 27-year-old man who was admitted to the emergency room because of sudden 4F ADB headache, nausea, vertigo, red eyes </del>and <del style="font-weight: bold; text-decoration: none;">palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available</del>.<br><del style="font-weight: bold; text-decoration: none;">Data availability </del><br><del style="font-weight: bold; text-decoration: none;">When clinical presentation and/</del>or <del style="font-weight: bold; text-decoration: none;">initial DOA testing results </del>are <del style="font-weight: bold; text-decoration: none;">inconclusive, additional testing </del>with <del style="font-weight: bold; text-decoration: none;">LC-QTOF-MS can be valuable </del>and <del style="font-weight: bold; text-decoration: none;">is recommended</del>. <del style="font-weight: bold; text-decoration: none;">SCRAs </del>and other <del style="font-weight: bold; text-decoration: none;">NPS may not be detected by point-</del>of<del style="font-weight: bold; text-decoration: none;">-care DOA tests</del>. <del style="font-weight: bold; text-decoration: none;">In this case</del>, the <del style="font-weight: bold; text-decoration: none;">point-of-care DOA urine screening </del>was <del style="font-weight: bold; text-decoration: none;">not able to detect </del>the <del style="font-weight: bold; text-decoration: none;">synthetic cannabinoid ADB-BUTINAC</del><br><br><del style="font-weight: bold; text-decoration: none;">Fig</del>. <del style="font-weight: bold; text-decoration: none;">2. <br>Separation </del>of <del style="font-weight: bold; text-decoration: none;">compounds was performed on a 2</del>.<del style="font-weight: bold; text-decoration: none;">1 mm×100 mm</del>, <del style="font-weight: bold; text-decoration: none;">1</del>.<del style="font-weight: bold; text-decoration: none;">7 4F ADB μm particle size ACQUITY Torus™ DIOL analytical column (Waters) with guard cartridge</del>. <del style="font-weight: bold; text-decoration: none;">Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system (Waters</del>) <del style="font-weight: bold; text-decoration: none;">coupled with a Xevo TQ</del>-<del style="font-weight: bold; text-decoration: none;">S Triple Quadrupole Mass Spectrometer (Waters)</del>. <del style="font-weight: bold; text-decoration: none;">During </del>the <del style="font-weight: bold; text-decoration: none;">death scene examination, multiple cigarette butts without filters were found </del>in <del style="font-weight: bold; text-decoration: none;">an ashtray; also found were alcohol bottles, an unopened box of nebivolol</del>-<del style="font-weight: bold; text-decoration: none;">containing drug, </del>and <del style="font-weight: bold; text-decoration: none;">18 g of unrecognizable herbal residue </del>in <del style="font-weight: bold; text-decoration: none;">a cigarette box</del>.<br><del style="font-weight: bold; text-decoration: none;">Data concerning </del>the <del style="font-weight: bold; text-decoration: none;">combined effects of SCRAs </del>and <del style="font-weight: bold; text-decoration: none;">other substances are highly limited</del>, <del style="font-weight: bold; text-decoration: none;">which renders forensic evaluation </del>of <del style="font-weight: bold; text-decoration: none;">possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng</del>/<del style="font-weight: bold; text-decoration: none;">mL level (0</del>.<del style="font-weight: bold; text-decoration: none;">37–4</del>.<del style="font-weight: bold; text-decoration: none;">1 ng/mL according to the reported cases</del>) <del style="font-weight: bold; text-decoration: none;">in cases in </del>which <del style="font-weight: bold; text-decoration: none;">1</del>.<del style="font-weight: bold; text-decoration: none;">5–2.5 g/L </del>of <del style="font-weight: bold; text-decoration: none;">ethanol is present in </del>the <del style="font-weight: bold; text-decoration: none;">blood. The victims </del>were <del style="font-weight: bold; text-decoration: none;">brothers who were both found deceased </del>after <del style="font-weight: bold; text-decoration: none;">consuming 4F-MDMB-BINACA and ethanol</del>. <del style="font-weight: bold; text-decoration: none;">These confusing shorter names </del>were <del style="font-weight: bold; text-decoration: none;">not scientifically adopted but were used by websites selling </del>the <del style="font-weight: bold; text-decoration: none;">drugs to </del>the <del style="font-weight: bold; text-decoration: none;">public. Monitoring metabolism </del>of <del style="font-weight: bold; text-decoration: none;">synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Briefly, the FOB test was comprised of several behavioral changes including catalepsy, traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex, and death. The FOB test was performed using published procedures (Moser et al., 1989) with some modifications. However, because of their subjective properties, it is necessary to set up a more objective automated measurement to determine their neurotoxicity. However, there are only a couple of anecdotal reports suspecting the possibility of their neurotoxicity with no scientific evidence (Cohen et al., 2012; McGuinness and Newell, 2012; Harris and Brown, 2013; Hermanns et al., 2013<br><br><br><ins style="font-weight: bold; text-decoration: none;">Test 2 was performed everyday for 5 days after consecutive administration </ins>of the <ins style="font-weight: bold; text-decoration: none;">substances, including negative </ins>(<ins style="font-weight: bold; text-decoration: none;">vehicle) </ins>and <ins style="font-weight: bold; text-decoration: none;">positive (methamphetamine</ins>) <ins style="font-weight: bold; text-decoration: none;">controls. After the last administration</ins>, <ins style="font-weight: bold; text-decoration: none;">the first trial was performed. Morris water maze test was performed to evaluate the changes of learning </ins>and <ins style="font-weight: bold; text-decoration: none;">memory function through administration of the test substances</ins>. <ins style="font-weight: bold; text-decoration: none;">Generally, neurotoxicity </ins>of <ins style="font-weight: bold; text-decoration: none;">a substance is evaluated </ins>by <ins style="font-weight: bold; text-decoration: none;">animal behavioral aspects, i.e</ins>. <ins style="font-weight: bold; text-decoration: none;">functional observation battery </ins>(<ins style="font-weight: bold; text-decoration: none;">FOB</ins>) <ins style="font-weight: bold; text-decoration: none;">tests (O’Callaghan et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2014)</ins>. <ins style="font-weight: bold; text-decoration: none;">Our results suggest that JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">081 </ins>and <ins style="font-weight: bold; text-decoration: none;">JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 may 4F ADB be neurotoxic substances through changing neuronal cell damages</ins>, <ins style="font-weight: bold; text-decoration: none;">especially </ins>in the <ins style="font-weight: bold; text-decoration: none;">core shell part </ins>of <ins style="font-weight: bold; text-decoration: none;">nucleus accumbens.<br>About Powder JWH-2</ins><br><br><ins style="font-weight: bold; text-decoration: none;">4. Drugs </ins><br><ins style="font-weight: bold; text-decoration: none;">In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 (Gatch et al., 2016), and 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">AMB produced sustained vocalization </ins>and <ins style="font-weight: bold; text-decoration: none;">convulsions in rats (Gatch et al., 2018). All </ins>of <ins style="font-weight: bold; text-decoration: none;">the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects </ins>of <ins style="font-weight: bold; text-decoration: none;">Δ9-THC. Subsequently</ins>, <ins style="font-weight: bold; text-decoration: none;">a one</ins>-<ins style="font-weight: bold; text-decoration: none;">way analysis </ins>of <ins style="font-weight: bold; text-decoration: none;">variance </ins>was <ins style="font-weight: bold; text-decoration: none;">conducted </ins>on <ins style="font-weight: bold; text-decoration: none;">horizontal activity counts for </ins>the <ins style="font-weight: bold; text-decoration: none;">30-min period </ins>of <ins style="font-weight: bold; text-decoration: none;">maximal effect, and planned comparisons were conducted for each dose against </ins>the <ins style="font-weight: bold; text-decoration: none;">vehicle control </ins>using <ins style="font-weight: bold; text-decoration: none;">single degree</ins>-of<ins style="font-weight: bold; text-decoration: none;">-freedom F tests</ins>. <ins style="font-weight: bold; text-decoration: none;">A two-way analysis </ins>of <ins style="font-weight: bold; text-decoration: none;">variance, with dose as </ins>a <ins style="font-weight: bold; text-decoration: none;">between groups factor </ins>and <ins style="font-weight: bold; text-decoration: none;">time as a within subject factor, was conducted on horizontal activity counts/10 min interval</ins>. <ins style="font-weight: bold; text-decoration: none;">Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally</ins>-<ins style="font-weight: bold; text-decoration: none;">active dose ranges and times </ins>of <ins style="font-weight: bold; text-decoration: none;">peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Michael B Gatch </ins><br><ins style="font-weight: bold; text-decoration: none;">Substantial depressant effects were observed within </ins>the <ins style="font-weight: bold; text-decoration: none;">first 10 min</ins>, <ins style="font-weight: bold; text-decoration: none;">and maximal depression was observed between 0–30 min following administration</ins>. <ins style="font-weight: bold; text-decoration: none;">Tremors were observed 30 minutes following 1 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA </ins>in <ins style="font-weight: bold; text-decoration: none;">3 </ins>of <ins style="font-weight: bold; text-decoration: none;">8 mice </ins>(<ins style="font-weight: bold; text-decoration: none;">data not shown</ins>)<ins style="font-weight: bold; text-decoration: none;">. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min </ins>and <ins style="font-weight: bold; text-decoration: none;">lasted up to 2.5 to 3 h at the 4F </ins>ADB <ins style="font-weight: bold; text-decoration: none;">highest dose tested </ins>(<ins style="font-weight: bold; text-decoration: none;">0.5 mg/kg</ins>).<ins style="font-weight: bold; text-decoration: none;"><br>Figure 1. <br>There is indication </ins>that <ins style="font-weight: bold; text-decoration: none;">at least some of </ins>the <ins style="font-weight: bold; text-decoration: none;">first</ins>-<ins style="font-weight: bold; text-decoration: none;">generation synthetic cannabinoids act at receptors other than cannabinoid CB1 </ins>and <ins style="font-weight: bold; text-decoration: none;">CB2 </ins>(<ins style="font-weight: bold; text-decoration: none;">Wiley et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2016</ins>)<ins style="font-weight: bold; text-decoration: none;">, and a compound from </ins>the <ins style="font-weight: bold; text-decoration: none;">present study, 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">PINACA, was found to activate midbrain dopamine neurons, but </ins>not <ins style="font-weight: bold; text-decoration: none;">serotonin neurons (Asaoka et al., 2016). As previously mentioned</ins>, <ins style="font-weight: bold; text-decoration: none;">all of </ins>the <ins style="font-weight: bold; text-decoration: none;">compounds tested in </ins>the <ins style="font-weight: bold; text-decoration: none;">present study (MDMB-PINACA, MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">CHMICA, MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, and AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA) act as agonists at CB1 receptors </ins>(<ins style="font-weight: bold; text-decoration: none;">Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC</ins>-<ins style="font-weight: bold; text-decoration: none;">like effects, including abuse liability</ins>. <ins style="font-weight: bold; text-decoration: none;">Tremors were not observed following AMB-FUBINACA during </ins>the <ins style="font-weight: bold; text-decoration: none;">drug discrimination study</ins>, <ins style="font-weight: bold; text-decoration: none;">but </ins>the <ins style="font-weight: bold; text-decoration: none;">maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than </ins>the <ins style="font-weight: bold; text-decoration: none;">dose that produced tremors in </ins>the <ins style="font-weight: bold; text-decoration: none;">mice.<br>Michael B Gat</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">In summary, JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 Chemical Powder stands out as a high</ins>-<ins style="font-weight: bold; text-decoration: none;">quality research compound designed for professionals who demand accuracy</ins>, <ins style="font-weight: bold; text-decoration: none;">consistency</ins>, and <ins style="font-weight: bold; text-decoration: none;">reliability. This commitment to 4F ADB quality makes it </ins>a <ins style="font-weight: bold; text-decoration: none;">trusted option for professionals who require dependable compounds for their work</ins>. <ins style="font-weight: bold; text-decoration: none;">From sourcing raw materials to final packaging</ins>, <ins style="font-weight: bold; text-decoration: none;">every stage </ins>of the <ins style="font-weight: bold; text-decoration: none;">process is monitored to ensure compliance with laboratory</ins>-<ins style="font-weight: bold; text-decoration: none;">grade expectations</ins>. <ins style="font-weight: bold; text-decoration: none;">This makes it an ideal choice for laboratories that prioritize both efficiency </ins>and <ins style="font-weight: bold; text-decoration: none;">compliance with research standards</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </ins><br><ins style="font-weight: bold; text-decoration: none;">In case of cannabis </ins>or <ins style="font-weight: bold; text-decoration: none;">Δ9-tetrahydrocannabinol, there </ins>are <ins style="font-weight: bold; text-decoration: none;">many [https://cannabinoidsrc4f-adb.com/ 4F ADB] previous studies regarding </ins>with <ins style="font-weight: bold; text-decoration: none;">their dependence potential </ins>and <ins style="font-weight: bold; text-decoration: none;">neurotoxicity (Cororan, et al., 1974; Harris, et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 1974; Leite </ins>and <ins style="font-weight: bold; text-decoration: none;">Culini, 1974; Hutcheson, et al., 1998). After administering test substances once every </ins>other <ins style="font-weight: bold; text-decoration: none;">day for 10 days, brain samples </ins>of <ins style="font-weight: bold; text-decoration: none;">mice were collected, especially at nucleus accumbens and hippocampus regions</ins>. <ins style="font-weight: bold; text-decoration: none;">Drug was administered 5 times every other day</ins>, <ins style="font-weight: bold; text-decoration: none;">and </ins>the <ins style="font-weight: bold; text-decoration: none;">first trial </ins>was <ins style="font-weight: bold; text-decoration: none;">performed 2 h after </ins>the <ins style="font-weight: bold; text-decoration: none;">last administration.</ins><br><ins style="font-weight: bold; text-decoration: none;">How to Choose Powder JWH-210 </ins><br><ins style="font-weight: bold; text-decoration: none;">When learning how to choose powder JWH-210, the most critical factor is verifying high chemical purity (≥98%) from a reputable supplier with independent lab testing</ins>. <ins style="font-weight: bold; text-decoration: none;">We also demonstrated that JWH-210 administration resulted in the decrease of expression levels </ins>of <ins style="font-weight: bold; text-decoration: none;">T-cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41, while JWH-030 increased Cd3g levels</ins>. <ins style="font-weight: bold; text-decoration: none;">JWH-210 (10 mg/kg, 3 days</ins>, <ins style="font-weight: bold; text-decoration: none;">i</ins>.<ins style="font-weight: bold; text-decoration: none;">p</ins>.) <ins style="font-weight: bold; text-decoration: none;">is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">030 of ICR mice in vivo</ins>. <ins style="font-weight: bold; text-decoration: none;">Users are expected to handle </ins>the <ins style="font-weight: bold; text-decoration: none;">compound </ins>in <ins style="font-weight: bold; text-decoration: none;">accordance with all applicable regulations and safety guidelines within their jurisdiction. It is important to note that JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity </ins>and <ins style="font-weight: bold; text-decoration: none;">stability has contributed to its widespread use </ins>in <ins style="font-weight: bold; text-decoration: none;">controlled environments where precision is paramount</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Is JWH-210 Legal? <br>A total of 2 and 3 methamphetamine treated mice fell from </ins>the <ins style="font-weight: bold; text-decoration: none;">spinning rod 30 min </ins>and <ins style="font-weight: bold; text-decoration: none;">2 hr after the administration, respectively. After the first injection</ins>, <ins style="font-weight: bold; text-decoration: none;">6 mice </ins>of <ins style="font-weight: bold; text-decoration: none;">the positive control group (methamphetamine, 5 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg, i</ins>.<ins style="font-weight: bold; text-decoration: none;">p</ins>.) <ins style="font-weight: bold; text-decoration: none;">showed loss of traction, of </ins>which <ins style="font-weight: bold; text-decoration: none;">4 showed tremor</ins>. <ins style="font-weight: bold; text-decoration: none;">Most </ins>of the <ins style="font-weight: bold; text-decoration: none;">abnormalities </ins>were <ins style="font-weight: bold; text-decoration: none;">normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals </ins>after <ins style="font-weight: bold; text-decoration: none;">2 hr of administration</ins>. <ins style="font-weight: bold; text-decoration: none;">Brain samples </ins>were <ins style="font-weight: bold; text-decoration: none;">prepared from </ins>the <ins style="font-weight: bold; text-decoration: none;">mice after </ins>the <ins style="font-weight: bold; text-decoration: none;">last administration </ins>of <ins style="font-weight: bold; text-decoration: none;">test substance</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=211194&oldid=prev EmmettWhitfield at 12:07, 22 May 2026 2026-05-22T12:07:50Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 12:07, 22 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018<br><br><br></del>These synthetic cannabinoids act <del style="font-weight: bold; text-decoration: none;">4F ADB </del>directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). <del style="font-weight: bold; text-decoration: none;">Discriminative stimulus effects were tested in rats trained </del>to <del style="font-weight: bold; text-decoration: none;">discriminate Δ9</del>-<del style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol </del>(<del style="font-weight: bold; text-decoration: none;">3 mg/kg</del>, <del style="font-weight: bold; text-decoration: none;">30-min pretreatment</del>). <del style="font-weight: bold; text-decoration: none;">5F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">PINACA </del>(also <del style="font-weight: bold; text-decoration: none;">known </del>as 5F-<del style="font-weight: bold; text-decoration: none;">ADB, 5F-ADB</del>-PINACA<del style="font-weight: bold; text-decoration: none;">), </del>MDMB-<del style="font-weight: bold; text-decoration: none;">CHIMICA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">ADB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA, and AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA </del>(<del style="font-weight: bold; text-decoration: none;">also known as FUB-AMB, MMB-FUBINACA</del>) <del style="font-weight: bold; text-decoration: none;">were tested </del>for <del style="font-weight: bold; text-decoration: none;">in vivo cannabinoid-like effects to assess their abuse liabilit</del><br><br><br><del style="font-weight: bold; text-decoration: none;">A limitation </del>of <del style="font-weight: bold; text-decoration: none;">this case report is that we did not have </del>a <del style="font-weight: bold; text-decoration: none;">urine sample available for additional NPS testing</del>. <del style="font-weight: bold; text-decoration: none;">Point</del>-of-care DOA <del style="font-weight: bold; text-decoration: none;">tests using </del>urine <del style="font-weight: bold; text-decoration: none;">to screen for misuse </del>of <del style="font-weight: bold; text-decoration: none;">multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines </del>and <del style="font-weight: bold; text-decoration: none;">methadone. THC</del>, <del style="font-weight: bold; text-decoration: none;">methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under </del>the <del style="font-weight: bold; text-decoration: none;">temperature </del>of <del style="font-weight: bold; text-decoration: none;">current </del>e-cigarettes, <del style="font-weight: bold; text-decoration: none;">while crack cocaine is hard to vaporise. A systematic review including data </del>of <del style="font-weight: bold; text-decoration: none;">114 patients of which the majority was intoxicated due to </del>SCRA <del style="font-weight: bold; text-decoration: none;">smoking revealed that 45 % of the patients who present at the ER after an </del>intoxication <del style="font-weight: bold; text-decoration: none;">due to SCRA smoking recovered within 24 hours </del>.<br>Data availability <br><del style="font-weight: bold; text-decoration: none;">Moreover</del>, <del style="font-weight: bold; text-decoration: none;">a study conducted in </del>the <del style="font-weight: bold; text-decoration: none;">United Kingdom investigated components </del>of <del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">liquids </del>in <del style="font-weight: bold; text-decoration: none;">112 samples originating from prisoners, teenagers </del>and <del style="font-weight: bold; text-decoration: none;">test purchases of commercially available e</del>-<del style="font-weight: bold; text-decoration: none;">cigarettes taken between 2014 and 2021 </del>. <del style="font-weight: bold; text-decoration: none;">This is the first case report </del>that <del style="font-weight: bold; text-decoration: none;">describes </del>the <del style="font-weight: bold; text-decoration: none;">toxicological symptoms of vaping </del>ADB-BUTINACA. <del style="font-weight: bold; text-decoration: none;">Results </del>of <del style="font-weight: bold; text-decoration: none;">the </del>DOA test (<del style="font-weight: bold; text-decoration: none;">including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants</del>) <del style="font-weight: bold; text-decoration: none;">were available within 30 minutes and were all negative</del>. <del style="font-weight: bold; text-decoration: none;">We report </del>a <del style="font-weight: bold; text-decoration: none;">case of an involuntary intoxication of </del>the <del style="font-weight: bold; text-decoration: none;">SCRA ADB-BUTINACA after vaping. There are several pitfalls in </del>the <del style="font-weight: bold; text-decoration: none;">detection </del>of <del style="font-weight: bold; text-decoration: none;">SCRA in samples taken from </del>the patient<del style="font-weight: bold; text-decoration: none;">.</del><br><del style="font-weight: bold; text-decoration: none;">Data availabili</del><br><br><del style="font-weight: bold; text-decoration: none;"><br>Similarly</del>, <del style="font-weight: bold; text-decoration: none;">precursor ion identified at m/z 380 (B19/B21</del>, <del style="font-weight: bold; text-decoration: none;">B23/B25) was 16 Da higher than </del>the <del style="font-weight: bold; text-decoration: none;">4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">BINACA</del>, <del style="font-weight: bold; text-decoration: none;">indicating monohydroxylation at </del>the <del style="font-weight: bold; text-decoration: none;">butyl side chain </del>(<del style="font-weight: bold; text-decoration: none;">B19/B21</del>) <del style="font-weight: bold; text-decoration: none;">and indazole (B23/B25) moieties with product ions m/z 145 and 161</del>, <del style="font-weight: bold; text-decoration: none;">respectively</del>. <del style="font-weight: bold; text-decoration: none;">Metabolites identified at m/z 366 (B8, B9, B13), which </del>was <del style="font-weight: bold; text-decoration: none;">16 Da higher than </del>the 4F<del style="font-weight: bold; text-decoration: none;">-MDMB-BINACA ester hydrolysis metabolite (B22), confirmed monohydroxylation upon ester hydrolysis. Death involving these drugs have been reported [5,6</del>,<del style="font-weight: bold; text-decoration: none;">7</del>,<del style="font-weight: bold; text-decoration: none;">8</del>,<del style="font-weight: bold; text-decoration: none;">9], and this raises public health </del>and <del style="font-weight: bold; text-decoration: none;">social concerns</del>. <del style="font-weight: bold; text-decoration: none;">Due to their similar physiological effects to the principal psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), SCBs </del>are gaining popularity and <del style="font-weight: bold; text-decoration: none;">are often abused as recreational drugs</del>. <del style="font-weight: bold; text-decoration: none;">The fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected in the postmortem blood samples of both victims suggests that both substances played a role in the fatal outcom</del><br><br><del style="font-weight: bold; text-decoration: none;"><br>In summary</del>, <del style="font-weight: bold; text-decoration: none;">JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 Chemical Powder stands out as a high</del>-<del style="font-weight: bold; text-decoration: none;">quality research compound designed for professionals who demand accuracy, consistency, </del>and <del style="font-weight: bold; text-decoration: none;">reliability</del>. <del style="font-weight: bold; text-decoration: none;">This commitment to [https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb</del>.<del style="font-weight: bold; text-decoration: none;">com/ 4F ADB] quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging</del>, <del style="font-weight: bold; text-decoration: none;">every stage </del>of the <del style="font-weight: bold; text-decoration: none;">process is monitored to ensure compliance with laboratory</del>-<del style="font-weight: bold; text-decoration: none;">grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.</del><br><del style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </del><br><del style="font-weight: bold; text-decoration: none;">Higher prices often reflect rigorous quality control rather than markup alone</del>. <del style="font-weight: bold; text-decoration: none;">This compound is appropriate only for authorized professionals conducting lawful research or analysis</del>. <del style="font-weight: bold; text-decoration: none;">For legitimate applications</del>, <del style="font-weight: bold; text-decoration: none;">only fully characterized, independently tested JWH-210 </del>4F ADB <del style="font-weight: bold; text-decoration: none;">should be considered</del>.<del style="font-weight: bold; text-decoration: none;"><br>How to Choose Powder JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 <br>When learning how to choose powder JWH-210, the most critical factor is verifying high chemical purity </del>(<del style="font-weight: bold; text-decoration: none;">≥98%</del>) <del style="font-weight: bold; text-decoration: none;">from a reputable supplier with independent lab testing</del>. <del style="font-weight: bold; text-decoration: none;">We </del>also <del style="font-weight: bold; text-decoration: none;">demonstrated that JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 administration resulted </del>in the <del style="font-weight: bold; text-decoration: none;">decrease of expression levels </del>of <del style="font-weight: bold; text-decoration: none;">T-cell activator including Cd3e, Cd3g, Cd74p31, </del>and <del style="font-weight: bold; text-decoration: none;">Cd74p41</del>, <del style="font-weight: bold; text-decoration: none;">while JWH-030 increased Cd3g levels</del>. <del style="font-weight: bold; text-decoration: none;">JWH-210 </del>(<del style="font-weight: bold; text-decoration: none;">10 mg</del>/<del style="font-weight: bold; text-decoration: none;">kg, 3 days, i</del>.<del style="font-weight: bold; text-decoration: none;">p</del>.<del style="font-weight: bold; text-decoration: none;">) </del>is <del style="font-weight: bold; text-decoration: none;">more likely to have cytotoxicity </del>and <del style="font-weight: bold; text-decoration: none;">reduce lymphoid organ weight than JWH-030 of ICR mice in vivo</del>. <del style="font-weight: bold; text-decoration: none;">Users are expected </del>to <del style="font-weight: bold; text-decoration: none;">handle </del>the <del style="font-weight: bold; text-decoration: none;">compound in accordance with all applicable regulations and safety guidelines within their jurisdiction</del>. <del style="font-weight: bold; text-decoration: none;">It is important to note that JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 Chemical Powder is intended strictly for research </del>and <del style="font-weight: bold; text-decoration: none;">laboratory use only</del>. <del style="font-weight: bold; text-decoration: none;">Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramoun</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014<ins style="font-weight: bold; text-decoration: none;"><br><br>Legal status <br>Briefly, the FOB test was comprised of several behavioral changes including catalepsy, traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex, and death. The FOB test was performed using published procedures (Moser et al., 1989</ins>) <ins style="font-weight: bold; text-decoration: none;">with some modifications</ins>. <ins style="font-weight: bold; text-decoration: none;">However, because of their subjective properties, it is necessary to set up a more objective automated measurement </ins>to <ins style="font-weight: bold; text-decoration: none;">determine their neurotoxicity. However, there are only a couple of anecdotal reports suspecting the possibility of their neurotoxicity with no scientific evidence (Cohen et al., 2012; McGuinness and Newell, 2012; Harris and Brown, 2013; Hermanns et al., 2013<br><br>Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR</ins>-<ins style="font-weight: bold; text-decoration: none;">144 by Cunninghamella elegans <br>The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour </ins>(<ins style="font-weight: bold; text-decoration: none;">intake route</ins>, <ins style="font-weight: bold; text-decoration: none;">amount of drug and intake frequency</ins>)<ins style="font-weight: bold; text-decoration: none;">, time from last drug intake and metabolic stability</ins>. <ins style="font-weight: bold; text-decoration: none;">This indicated that the phase I metabolism of 4F</ins>-MDMB-<ins style="font-weight: bold; text-decoration: none;">BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation </ins>(<ins style="font-weight: bold; text-decoration: none;">B17) metabolite, the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed in-vivo in this study was </ins>also <ins style="font-weight: bold; text-decoration: none;">reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such </ins>as 5F-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-PINACA <ins style="font-weight: bold; text-decoration: none;">and </ins>MDMB-<ins style="font-weight: bold; text-decoration: none;">4en-PINACA [39</ins>, <ins style="font-weight: bold; text-decoration: none;">40]. Similar to the in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo findings</ins>, <ins style="font-weight: bold; text-decoration: none;">4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA ester hydrolysis </ins>(<ins style="font-weight: bold; text-decoration: none;">B22</ins>) <ins style="font-weight: bold; text-decoration: none;">was the major metabolite </ins>for <ins style="font-weight: bold; text-decoration: none;">both HepG2 and HLM models, consistent with the known hydrolytic activity of CES reported</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification </ins>of a <ins style="font-weight: bold; text-decoration: none;">broad spectrum of recreational drugs, including new psychoactive substances</ins>. <ins style="font-weight: bold; text-decoration: none;">A point</ins>-of-care <ins style="font-weight: bold; text-decoration: none;">drugs of abuse (</ins>DOA<ins style="font-weight: bold; text-decoration: none;">) test was initially performed on the </ins>urine of <ins style="font-weight: bold; text-decoration: none;">the patient. He confirmed drinking 750 ml energy drink without any further consumption of food </ins>and <ins style="font-weight: bold; text-decoration: none;">using an e-cigarette from Gaziantep</ins>, <ins style="font-weight: bold; text-decoration: none;">Turkey 10 seconds before </ins>the <ins style="font-weight: bold; text-decoration: none;">onset </ins>of <ins style="font-weight: bold; text-decoration: none;">his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes </ins>e-cigarettes<ins style="font-weight: bold; text-decoration: none;">. Combined with non-specific</ins>, <ins style="font-weight: bold; text-decoration: none;">transient symptoms, clinical recognition </ins>of SCRA intoxication <ins style="font-weight: bold; text-decoration: none;">is challenging </ins>.<br>Data availability <br><ins style="font-weight: bold; text-decoration: none;">The intensity is plotted against the retention time for both chromatograms</ins>, <ins style="font-weight: bold; text-decoration: none;">demonstrating </ins>the <ins style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f-adb.com/ 4F ADB] presence and elution profiles </ins>of <ins style="font-weight: bold; text-decoration: none;">nicotine and ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINACA </ins>in <ins style="font-weight: bold; text-decoration: none;">the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) </ins>and <ins style="font-weight: bold; text-decoration: none;">ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINACA (Bottom) in the Vape Liquid used by the patient</ins>. <ins style="font-weight: bold; text-decoration: none;">The LC-QTOF-MS analysis showed </ins>that the <ins style="font-weight: bold; text-decoration: none;">e-liquid contained nicotine and </ins>ADB-BUTINACA <ins style="font-weight: bold; text-decoration: none;">(Fig. 1)</ins>. <ins style="font-weight: bold; text-decoration: none;">Because the point-</ins>of<ins style="font-weight: bold; text-decoration: none;">-care </ins>DOA test <ins style="font-weight: bold; text-decoration: none;">is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry </ins>(<ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS</ins>) <ins style="font-weight: bold; text-decoration: none;">on the Waters™ Xevo G3 QTOF MS system</ins>. <ins style="font-weight: bold; text-decoration: none;">After eating </ins>a <ins style="font-weight: bold; text-decoration: none;">light meal and drinking caffeinated sports drinks at </ins>the <ins style="font-weight: bold; text-decoration: none;">ER, </ins>the <ins style="font-weight: bold; text-decoration: none;">nausea complaints </ins>of the patient <ins style="font-weight: bold; text-decoration: none;">were reduced and the patient was discharged hom</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity</ins>, <ins style="font-weight: bold; text-decoration: none;">specificity</ins>, <ins style="font-weight: bold; text-decoration: none;">and a broader spectrum of detectable substances. Despite all negative results in </ins>the <ins style="font-weight: bold; text-decoration: none;">point</ins>-<ins style="font-weight: bold; text-decoration: none;">of</ins>-<ins style="font-weight: bold; text-decoration: none;">care test for recreational drugs</ins>, the <ins style="font-weight: bold; text-decoration: none;">liquid chromatography-quadrupole time-of-flight mass spectrometry </ins>(<ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS</ins>) <ins style="font-weight: bold; text-decoration: none;">analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">a synthetic cannabinoid</ins>. <ins style="font-weight: bold; text-decoration: none;">We report a 27-year-old man who </ins>was <ins style="font-weight: bold; text-decoration: none;">admitted to </ins>the <ins style="font-weight: bold; text-decoration: none;">emergency room because of sudden </ins>4F <ins style="font-weight: bold; text-decoration: none;">ADB headache</ins>, <ins style="font-weight: bold; text-decoration: none;">nausea</ins>, <ins style="font-weight: bold; text-decoration: none;">vertigo</ins>, <ins style="font-weight: bold; text-decoration: none;">red eyes </ins>and <ins style="font-weight: bold; text-decoration: none;">palpitations</ins>. <ins style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids </ins>are gaining popularity <ins style="font-weight: bold; text-decoration: none;">globally </ins>and <ins style="font-weight: bold; text-decoration: none;">detection is not commonly available</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Data availability </ins><br><ins style="font-weight: bold; text-decoration: none;">When clinical presentation and/or initial DOA testing results are inconclusive</ins>, <ins style="font-weight: bold; text-decoration: none;">additional testing with LC</ins>-<ins style="font-weight: bold; text-decoration: none;">QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS can be valuable </ins>and <ins style="font-weight: bold; text-decoration: none;">is recommended</ins>. <ins style="font-weight: bold; text-decoration: none;">SCRAs and other NPS may not be detected by point-of</ins>-<ins style="font-weight: bold; text-decoration: none;">care DOA tests</ins>. <ins style="font-weight: bold; text-decoration: none;">In this case</ins>, <ins style="font-weight: bold; text-decoration: none;">the point-</ins>of<ins style="font-weight: bold; text-decoration: none;">-care DOA urine screening was not able to detect </ins>the <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoid ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINAC</ins><br><br><ins style="font-weight: bold; text-decoration: none;">Fig. 2</ins>. <ins style="font-weight: bold; text-decoration: none;"><br>Separation of compounds was performed on a 2</ins>.<ins style="font-weight: bold; text-decoration: none;">1 mm×100 mm</ins>, <ins style="font-weight: bold; text-decoration: none;">1.7 </ins>4F ADB <ins style="font-weight: bold; text-decoration: none;">μm particle size ACQUITY Torus™ DIOL analytical column (Waters) with guard cartridge</ins>. <ins style="font-weight: bold; text-decoration: none;">Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system (Waters) coupled with a Xevo TQ</ins>-<ins style="font-weight: bold; text-decoration: none;">S Triple Quadrupole Mass Spectrometer </ins>(<ins style="font-weight: bold; text-decoration: none;">Waters</ins>). <ins style="font-weight: bold; text-decoration: none;">During the death scene examination, multiple cigarette butts without filters were found in an ashtray; </ins>also <ins style="font-weight: bold; text-decoration: none;">found were alcohol bottles, an unopened box of nebivolol</ins>-<ins style="font-weight: bold; text-decoration: none;">containing drug, and 18 g of unrecognizable herbal residue </ins>in <ins style="font-weight: bold; text-decoration: none;">a cigarette box.<br>Data concerning </ins>the <ins style="font-weight: bold; text-decoration: none;">combined effects </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRAs </ins>and <ins style="font-weight: bold; text-decoration: none;">other substances are highly limited</ins>, <ins style="font-weight: bold; text-decoration: none;">which renders forensic evaluation of possible overdose cases difficult </ins>. <ins style="font-weight: bold; text-decoration: none;">The threshold SCRA concentration for fatal overdose can be estimated ng/mL level </ins>(<ins style="font-weight: bold; text-decoration: none;">0.37–4.1 ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL according to the reported cases) in cases in which 1</ins>.<ins style="font-weight: bold; text-decoration: none;">5–2</ins>.<ins style="font-weight: bold; text-decoration: none;">5 g/L of ethanol </ins>is <ins style="font-weight: bold; text-decoration: none;">present in the blood. The victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA </ins>and <ins style="font-weight: bold; text-decoration: none;">ethanol</ins>. <ins style="font-weight: bold; text-decoration: none;">These confusing shorter names were not scientifically adopted but were used by websites selling the drugs </ins>to the <ins style="font-weight: bold; text-decoration: none;">public</ins>. <ins style="font-weight: bold; text-decoration: none;">Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes </ins>and <ins style="font-weight: bold; text-decoration: none;">confirmed using urine samples</ins>. <ins style="font-weight: bold; text-decoration: none;">This article does not contain any studies with human participants or animals performed by any of the author</ins></div></td></tr> </table>

EmmettWhitfield https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=211188&oldid=prev DamonAngas210 at 12:05, 22 May 2026 2026-05-22T12:05:59Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 12:05, 22 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Buy Jwh</del>-<del style="font-weight: bold; text-decoration: none;">210 </del>at <del style="font-weight: bold; text-decoration: none;">USA K2 INCENSE STORE </del>and <del style="font-weight: bold; text-decoration: none;">enjoy premium quality</del>, <del style="font-weight: bold; text-decoration: none;">flexible quantities</del>, and <del style="font-weight: bold; text-decoration: none;">fast</del>, <del style="font-weight: bold; text-decoration: none;">secure shipping</del>. <del style="font-weight: bold; text-decoration: none;">Fast shipping and pure product</del>-<del style="font-weight: bold; text-decoration: none;">highly recommended for anyone needing quality incense ingredients</del>.<del style="font-weight: bold; text-decoration: none;">" 🌟🌟🌟🌟🌟 You can buy jwh</del>-<del style="font-weight: bold; text-decoration: none;">210 online in quantities of 5CL ADBA powder 10g</del>, <del style="font-weight: bold; text-decoration: none;">30g</del>, <del style="font-weight: bold; text-decoration: none;">50g</del>, <del style="font-weight: bold; text-decoration: none;">100g</del>, <del style="font-weight: bold; text-decoration: none;">150g</del>, and <del style="font-weight: bold; text-decoration: none;">200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it is classified </del>as <del style="font-weight: bold; text-decoration: none;">a controlled substance</del>, <del style="font-weight: bold; text-decoration: none;">while </del>in <del style="font-weight: bold; text-decoration: none;">others, it may be legal for research or incense use. The legal status of jwh</del>-<del style="font-weight: bold; text-decoration: none;">210 varies by country and region.</del><br> <del style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </del><br><del style="font-weight: bold; text-decoration: none;">In </del>case of <del style="font-weight: bold; text-decoration: none;">cannabis or Δ9</del>-<del style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol</del>, <del style="font-weight: bold; text-decoration: none;">there are many 5CL ADBA powder previous studies regarding with their dependence potential and neurotoxicity (Cororan</del>, <del style="font-weight: bold; text-decoration: none;">et al.</del>, <del style="font-weight: bold; text-decoration: none;">1974; Harris</del>, <del style="font-weight: bold; text-decoration: none;">et al.</del>, <del style="font-weight: bold; text-decoration: none;">1974; Leite </del>and <del style="font-weight: bold; text-decoration: none;">Culini</del>, <del style="font-weight: bold; text-decoration: none;">1974; Hutcheson</del>, <del style="font-weight: bold; text-decoration: none;">et al.</del>, <del style="font-weight: bold; text-decoration: none;">1998</del>)<del style="font-weight: bold; text-decoration: none;">. After administering test substances once every other day for 10 days</del>, <del style="font-weight: bold; text-decoration: none;">brain samples </del>of <del style="font-weight: bold; text-decoration: none;">mice were collected</del>, <del style="font-weight: bold; text-decoration: none;">especially at nucleus accumbens and hippocampus regions</del>. <del style="font-weight: bold; text-decoration: none;">Drug </del>was <del style="font-weight: bold; text-decoration: none;">administered 5 times every other day, and </del>the <del style="font-weight: bold; text-decoration: none;">first trial was performed 2 h </del>after <del style="font-weight: bold; text-decoration: none;">the last administration</del>.<br> <del style="font-weight: bold; text-decoration: none;">How to Choose Powder JWH-210 </del><br><del style="font-weight: bold; text-decoration: none;">This dual-use nature underscores </del>the <del style="font-weight: bold; text-decoration: none;">importance </del>of <del style="font-weight: bold; text-decoration: none;">responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers</del>, and <del style="font-weight: bold; text-decoration: none;">customs officials use authentic samples like JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 to distinguish </del>between <del style="font-weight: bold; text-decoration: none;">legal </del>and <del style="font-weight: bold; text-decoration: none;">illegal compounds in seized materials</del>. <del style="font-weight: bold; text-decoration: none;">For those seeking a dependable compound </del>for <del style="font-weight: bold; text-decoration: none;">analytical purposes</del>, <del style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process</del>, <del style="font-weight: bold; text-decoration: none;">stable composition</del>, <del style="font-weight: bold; text-decoration: none;">and secure packaging</del>, <del style="font-weight: bold; text-decoration: none;">it remains a valuable resource for laboratory-based research.<br> Is JWH-210 Legal? <br>A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration</del>, <del style="font-weight: bold; text-decoration: none;">respectively. After the first injection</del>, <del style="font-weight: bold; text-decoration: none;">6 mice of the positive control group (methamphetamine</del>, <del style="font-weight: bold; text-decoration: none;">5 mg/kg</del>, <del style="font-weight: bold; text-decoration: none;">i</del>.<del style="font-weight: bold; text-decoration: none;">p.) showed loss </del>of <del style="font-weight: bold; text-decoration: none;">traction, </del>of <del style="font-weight: bold; text-decoration: none;">which 4 showed tremor</del>. <del style="font-weight: bold; text-decoration: none;">Most </del>of <del style="font-weight: bold; text-decoration: none;">the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained </del>in <del style="font-weight: bold; text-decoration: none;">methamphetamine treated animals after 2 hr of administration. Brain </del>samples <del style="font-weight: bold; text-decoration: none;">were prepared </del>from the <del style="font-weight: bold; text-decoration: none;">mice after the last administration of test substance</del><br><br><br><del style="font-weight: bold; text-decoration: none;">After the incubation</del>, <del style="font-weight: bold; text-decoration: none;">mixture was centrifuged </del>(<del style="font-weight: bold; text-decoration: none;">18</del>,<del style="font-weight: bold; text-decoration: none;">000 x g, 20 °C</del>) <del style="font-weight: bold; text-decoration: none;">for 5 min and 0.5 μL of the supernatant </del>was <del style="font-weight: bold; text-decoration: none;">directly injected to </del>the <del style="font-weight: bold; text-decoration: none;">chromatographic system. In the next step</del>, <del style="font-weight: bold; text-decoration: none;">ammonium formate as salting agent was added to </del>the <del style="font-weight: bold; text-decoration: none;">mixture </del>and <del style="font-weight: bold; text-decoration: none;">incubated in a thermomixer </del>(<del style="font-weight: bold; text-decoration: none;">20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand 5CL ADBA powder at room temperature for 5 min. MS</del>/<del style="font-weight: bold; text-decoration: none;">MS experiments were performed in MRM (multiple reaction monitoring</del>) <del style="font-weight: bold; text-decoration: none;">mode </del>with <del style="font-weight: bold; text-decoration: none;">an isolation window of 0</del>.<del style="font-weight: bold; text-decoration: none;">4 </del>m/z<del style="font-weight: bold; text-decoration: none;">. The MS measurement </del>was <del style="font-weight: bold; text-decoration: none;">performed in positive ion mode </del>(<del style="font-weight: bold; text-decoration: none;">except for some acidic compounds such as barbiturates<br><br> 4</del>. <del style="font-weight: bold; text-decoration: none;">Drugs <br>In general, the locomotor depressant and discriminative stimulus effects </del>have been <del style="font-weight: bold; text-decoration: none;">observed at doses that do not produce adverse effects</del>, <del style="font-weight: bold; text-decoration: none;">although tremors were observed upon handling in mice that received JWH-210 (Gatch et al.</del>, <del style="font-weight: bold; text-decoration: none;">2016)</del>, and <del style="font-weight: bold; text-decoration: none;">5F-AMB produced sustained vocalization </del>and <del style="font-weight: bold; text-decoration: none;">convulsions in rats (Gatch et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2018). All of the synthetic cannabinoids tested in </del>the <del style="font-weight: bold; text-decoration: none;">present study fully substituted for the discriminative stimulus effects </del>of Δ9-THC. <del style="font-weight: bold; text-decoration: none;">Subsequently, a one</del>-<del style="font-weight: bold; text-decoration: none;">way analysis of variance was conducted on horizontal activity counts for the 30</del>-<del style="font-weight: bold; text-decoration: none;">min period of maximal effect, </del>and <del style="font-weight: bold; text-decoration: none;">planned comparisons </del>were <del style="font-weight: bold; text-decoration: none;">conducted for each dose against </del>the <del style="font-weight: bold; text-decoration: none;">vehicle control using single degree-</del>of<del style="font-weight: bold; text-decoration: none;">-freedom F tests. A two-way analysis of variance, with dose as </del>a <del style="font-weight: bold; text-decoration: none;">between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity </del>in <del style="font-weight: bold; text-decoration: none;">mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at </del>the <del style="font-weight: bold; text-decoration: none;">CB1 receptor.</del><br> <del style="font-weight: bold; text-decoration: none;">Michael B Gatch </del><br><del style="font-weight: bold; text-decoration: none;">Substantial depressant effects were observed within the first 10 min</del>, <del style="font-weight: bold; text-decoration: none;">and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min</del>, and <del style="font-weight: bold; text-decoration: none;">maximal depression was observed between 10–40 min and lasted up to 2</del>.<del style="font-weight: bold; text-decoration: none;">5 </del>to <del style="font-weight: bold; text-decoration: none;">3 h at the </del>[https://cannabinoidsrc4f-adb.com/ <del style="font-weight: bold; text-decoration: none;">5CL ADBA powder</del>] <del style="font-weight: bold; text-decoration: none;">highest dose tested (0</del>.<del style="font-weight: bold; text-decoration: none;">5 mg/kg)</del>.<br> <del style="font-weight: bold; text-decoration: none;">Figure 1. </del><br><del style="font-weight: bold; text-decoration: none;">There </del>is <del style="font-weight: bold; text-decoration: none;">indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al</del>., <del style="font-weight: bold; text-decoration: none;">2016)</del>, <del style="font-weight: bold; text-decoration: none;">and a compound from the present study, 5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA, was found </del>to <del style="font-weight: bold; text-decoration: none;">activate midbrain dopamine neurons</del>, <del style="font-weight: bold; text-decoration: none;">but not serotonin neurons </del>(<del style="font-weight: bold; text-decoration: none;">Asaoka et al., 2016</del>). <del style="font-weight: bold; text-decoration: none;">As previously mentioned, all of the compounds tested </del>in the <del style="font-weight: bold; text-decoration: none;">present study (MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-CHMICA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">ADB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA, and AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA) act as agonists at CB1 receptors </del>(<del style="font-weight: bold; text-decoration: none;">Banister et al.</del>, <del style="font-weight: bold; text-decoration: none;">2015</del>, <del style="font-weight: bold; text-decoration: none;">2016; Gamage et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2018</del>)<del style="font-weight: bold; text-decoration: none;">, which suggests these compounds will produce Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC-like effects, including abuse liability</del>. <del style="font-weight: bold; text-decoration: none;">Tremors were not observed following AMB-FUBINACA during </del>the <del style="font-weight: bold; text-decoration: none;">drug discrimination study, but the maximum dose tested was only 0</del>.<del style="font-weight: bold; text-decoration: none;">1 mg/kg, which </del>is <del style="font-weight: bold; text-decoration: none;">10</del>-<del style="font-weight: bold; text-decoration: none;">fold lower than the dose that produced tremors </del>in <del style="font-weight: bold; text-decoration: none;">the mic</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those of Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018<br><br><br>These synthetic cannabinoids act 4F ADB directly </ins>at <ins style="font-weight: bold; text-decoration: none;">cannabinoid CB1 </ins>and <ins style="font-weight: bold; text-decoration: none;">CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC</ins>, <ins style="font-weight: bold; text-decoration: none;">different metabolism</ins>, and <ins style="font-weight: bold; text-decoration: none;">often greater toxicity (Fantegrossi et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2014)</ins>. <ins style="font-weight: bold; text-decoration: none;">Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30</ins>-<ins style="font-weight: bold; text-decoration: none;">min pretreatment)</ins>. <ins style="font-weight: bold; text-decoration: none;">5F-MDMB-PINACA (also known as 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">ADB</ins>, <ins style="font-weight: bold; text-decoration: none;">5F-ADB-PINACA)</ins>, <ins style="font-weight: bold; text-decoration: none;">MDMB-CHIMICA</ins>, <ins style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">ADB-FUBINACA</ins>, and <ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA (also known </ins>as <ins style="font-weight: bold; text-decoration: none;">FUB-AMB</ins>, <ins style="font-weight: bold; text-decoration: none;">MMB-FUBINACA) were tested for </ins>in <ins style="font-weight: bold; text-decoration: none;">vivo cannabinoid</ins>-<ins style="font-weight: bold; text-decoration: none;">like effects to assess their abuse liabilit<br></ins><br><br><ins style="font-weight: bold; text-decoration: none;">A limitation of this </ins>case <ins style="font-weight: bold; text-decoration: none;">report is that we did not have a urine sample available for additional NPS testing. Point-</ins>of-<ins style="font-weight: bold; text-decoration: none;">care DOA tests using urine to screen for misuse of multiple substances</ins>, <ins style="font-weight: bold; text-decoration: none;">regularly include cannabis</ins>, <ins style="font-weight: bold; text-decoration: none;">amphetamines</ins>, <ins style="font-weight: bold; text-decoration: none;">cocaine</ins>, <ins style="font-weight: bold; text-decoration: none;">opioids</ins>, <ins style="font-weight: bold; text-decoration: none;">benzodiazepines </ins>and <ins style="font-weight: bold; text-decoration: none;">methadone. THC</ins>, <ins style="font-weight: bold; text-decoration: none;">methamphetamine</ins>, <ins style="font-weight: bold; text-decoration: none;">SRCA</ins>, <ins style="font-weight: bold; text-decoration: none;">lysergic acid diethylamide (LSD</ins>), <ins style="font-weight: bold; text-decoration: none;">gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature </ins>of <ins style="font-weight: bold; text-decoration: none;">current e-cigarettes</ins>, <ins style="font-weight: bold; text-decoration: none;">while crack cocaine is hard to vaporise</ins>. <ins style="font-weight: bold; text-decoration: none;">A systematic review including data of 114 patients of which the majority </ins>was <ins style="font-weight: bold; text-decoration: none;">intoxicated due to SCRA smoking revealed that 45 % of the patients who present at </ins>the <ins style="font-weight: bold; text-decoration: none;">ER </ins>after <ins style="font-weight: bold; text-decoration: none;">an intoxication due to SCRA smoking recovered within 24 hours </ins>.<br><ins style="font-weight: bold; text-decoration: none;">Data availability </ins><br><ins style="font-weight: bold; text-decoration: none;">Moreover, a study conducted in </ins>the <ins style="font-weight: bold; text-decoration: none;">United Kingdom investigated components </ins>of <ins style="font-weight: bold; text-decoration: none;">e-liquids in 112 samples originating from prisoners</ins>, <ins style="font-weight: bold; text-decoration: none;">teenagers </ins>and <ins style="font-weight: bold; text-decoration: none;">test purchases of commercially available e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarettes taken </ins>between <ins style="font-weight: bold; text-decoration: none;">2014 </ins>and <ins style="font-weight: bold; text-decoration: none;">2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA</ins>. <ins style="font-weight: bold; text-decoration: none;">Results of the DOA test (including testing </ins>for <ins style="font-weight: bold; text-decoration: none;">amphetamines</ins>, <ins style="font-weight: bold; text-decoration: none;">methamphetamines</ins>, <ins style="font-weight: bold; text-decoration: none;">barbiturates</ins>, <ins style="font-weight: bold; text-decoration: none;">benzodiazepines</ins>, <ins style="font-weight: bold; text-decoration: none;">cocaine</ins>, <ins style="font-weight: bold; text-decoration: none;">methadone</ins>, <ins style="font-weight: bold; text-decoration: none;">opioids</ins>, <ins style="font-weight: bold; text-decoration: none;">cannabis</ins>, <ins style="font-weight: bold; text-decoration: none;">tricyclic antidepressants) were available within 30 minutes and were all negative</ins>. <ins style="font-weight: bold; text-decoration: none;">We report a case </ins>of <ins style="font-weight: bold; text-decoration: none;">an involuntary intoxication </ins>of <ins style="font-weight: bold; text-decoration: none;">the SCRA ADB-BUTINACA after vaping</ins>. <ins style="font-weight: bold; text-decoration: none;">There are several pitfalls in the detection </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRA </ins>in samples <ins style="font-weight: bold; text-decoration: none;">taken </ins>from the <ins style="font-weight: bold; text-decoration: none;">patient.<br>Data availabili</ins><br><br><br><ins style="font-weight: bold; text-decoration: none;">Similarly</ins>, <ins style="font-weight: bold; text-decoration: none;">precursor ion identified at m/z 380 </ins>(<ins style="font-weight: bold; text-decoration: none;">B19/B21</ins>, <ins style="font-weight: bold; text-decoration: none;">B23/B25</ins>) was <ins style="font-weight: bold; text-decoration: none;">16 Da higher than </ins>the <ins style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">indicating monohydroxylation at </ins>the <ins style="font-weight: bold; text-decoration: none;">butyl side chain (B19/B21) </ins>and <ins style="font-weight: bold; text-decoration: none;">indazole </ins>(<ins style="font-weight: bold; text-decoration: none;">B23</ins>/<ins style="font-weight: bold; text-decoration: none;">B25</ins>) <ins style="font-weight: bold; text-decoration: none;">moieties </ins>with <ins style="font-weight: bold; text-decoration: none;">product ions m/z 145 and 161, respectively</ins>. <ins style="font-weight: bold; text-decoration: none;">Metabolites identified at </ins>m/z <ins style="font-weight: bold; text-decoration: none;">366 (B8, B9, B13), which </ins>was <ins style="font-weight: bold; text-decoration: none;">16 Da higher than the 4F-MDMB-BINACA ester hydrolysis metabolite </ins>(<ins style="font-weight: bold; text-decoration: none;">B22), confirmed monohydroxylation upon ester hydrolysis</ins>. <ins style="font-weight: bold; text-decoration: none;">Death involving these drugs </ins>have been <ins style="font-weight: bold; text-decoration: none;">reported [5,6,7</ins>,<ins style="font-weight: bold; text-decoration: none;">8</ins>,<ins style="font-weight: bold; text-decoration: none;">9]</ins>, and <ins style="font-weight: bold; text-decoration: none;">this raises public health </ins>and <ins style="font-weight: bold; text-decoration: none;">social concerns</ins>. <ins style="font-weight: bold; text-decoration: none;">Due to their similar physiological effects to </ins>the <ins style="font-weight: bold; text-decoration: none;">principal psychoactive component </ins>of <ins style="font-weight: bold; text-decoration: none;">cannabis, </ins>Δ9-<ins style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol (</ins>THC<ins style="font-weight: bold; text-decoration: none;">), SCBs are gaining popularity and are often abused as recreational drugs</ins>. <ins style="font-weight: bold; text-decoration: none;">The fact that similar 4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA </ins>and <ins style="font-weight: bold; text-decoration: none;">ethanol concentrations </ins>were <ins style="font-weight: bold; text-decoration: none;">detected in </ins>the <ins style="font-weight: bold; text-decoration: none;">postmortem blood samples </ins>of <ins style="font-weight: bold; text-decoration: none;">both victims suggests that both substances played </ins>a <ins style="font-weight: bold; text-decoration: none;">role </ins>in the <ins style="font-weight: bold; text-decoration: none;">fatal outcom<br></ins><br><br><ins style="font-weight: bold; text-decoration: none;">In summary</ins>, <ins style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder stands out as a high</ins>-<ins style="font-weight: bold; text-decoration: none;">quality research compound designed for professionals who demand accuracy, consistency</ins>, and <ins style="font-weight: bold; text-decoration: none;">reliability</ins>. <ins style="font-weight: bold; text-decoration: none;">This commitment </ins>to [https://cannabinoidsrc4f-adb.com/ <ins style="font-weight: bold; text-decoration: none;">4F ADB</ins>] <ins style="font-weight: bold; text-decoration: none;">quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations</ins>. <ins style="font-weight: bold; text-decoration: none;">This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards</ins>.<br><ins style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </ins><br><ins style="font-weight: bold; text-decoration: none;">Higher prices often reflect rigorous quality control rather than markup alone. This compound </ins>is <ins style="font-weight: bold; text-decoration: none;">appropriate only for authorized professionals conducting lawful research or analysis</ins>. <ins style="font-weight: bold; text-decoration: none;">For legitimate applications</ins>, <ins style="font-weight: bold; text-decoration: none;">only fully characterized</ins>, <ins style="font-weight: bold; text-decoration: none;">independently tested JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 4F ADB should be considered.<br>How to Choose Powder JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 <br>When learning how </ins>to <ins style="font-weight: bold; text-decoration: none;">choose powder JWH-210</ins>, <ins style="font-weight: bold; text-decoration: none;">the most critical factor is verifying high chemical purity </ins>(<ins style="font-weight: bold; text-decoration: none;">≥98%</ins>) <ins style="font-weight: bold; text-decoration: none;">from a reputable supplier with independent lab testing</ins>. <ins style="font-weight: bold; text-decoration: none;">We also demonstrated that JWH-210 administration resulted </ins>in the <ins style="font-weight: bold; text-decoration: none;">decrease of expression levels of T</ins>-<ins style="font-weight: bold; text-decoration: none;">cell activator including Cd3e, Cd3g</ins>, <ins style="font-weight: bold; text-decoration: none;">Cd74p31</ins>, <ins style="font-weight: bold; text-decoration: none;">and Cd74p41</ins>, <ins style="font-weight: bold; text-decoration: none;">while JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">030 increased Cd3g levels. JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 </ins>(<ins style="font-weight: bold; text-decoration: none;">10 mg/kg</ins>, <ins style="font-weight: bold; text-decoration: none;">3 days</ins>, <ins style="font-weight: bold; text-decoration: none;">i.p</ins>.) <ins style="font-weight: bold; text-decoration: none;">is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">030 of ICR mice in vivo</ins>. <ins style="font-weight: bold; text-decoration: none;">Users are expected to handle </ins>the <ins style="font-weight: bold; text-decoration: none;">compound in accordance with all applicable regulations and safety guidelines within their jurisdiction</ins>. <ins style="font-weight: bold; text-decoration: none;">It </ins>is <ins style="font-weight: bold; text-decoration: none;">important to note that JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use </ins>in <ins style="font-weight: bold; text-decoration: none;">controlled environments where precision is paramoun</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&diff=209606&oldid=prev ChongRede5 at 07:03, 21 May 2026 2026-05-21T07:03:54Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 07:03, 21 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patien<br><br><br>LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.<br>Data availabili<br><br><br>Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at 5CLADBA least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat<br><br>The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 <br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the [https://cannabinoidsrc4f-adb.com/ 5CLADBA] presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom<br><br>These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014<br><br><br></del>Buy Jwh-210 at USA K2 INCENSE STORE and enjoy premium quality, flexible quantities, and fast, secure shipping. Fast shipping and pure product-highly recommended for anyone needing quality incense ingredients." 🌟🌟🌟🌟🌟 You can buy jwh-210 online in quantities of <del style="font-weight: bold; text-decoration: none;">5CLADBA </del>10g, 30g, 50g, 100g, 150g, and 200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it is classified as a controlled substance, while in others, it may be legal for research or incense use. The legal status of jwh-210 varies by country and region.<br> Key Features and Specifications to Evaluate <br>In case of cannabis or Δ9-tetrahydrocannabinol, there are many <del style="font-weight: bold; text-decoration: none;">5CLADBA </del>previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998). After administering test substances once every other day for 10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day, and the first trial was performed 2 h after the last administration.<br> How to Choose Powder JWH-210 <br>This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based research.<br> Is JWH-210 Legal? <br>A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively. After the first injection, 6 mice of the positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Buy Jwh-210 at USA K2 INCENSE STORE and enjoy premium quality, flexible quantities, and fast, secure shipping. Fast shipping and pure product-highly recommended for anyone needing quality incense ingredients." 🌟🌟🌟🌟🌟 You can buy jwh-210 online in quantities of <ins style="font-weight: bold; text-decoration: none;">5CL ADBA powder </ins>10g, 30g, 50g, 100g, 150g, and 200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it is classified as a controlled substance, while in others, it may be legal for research or incense use. The legal status of jwh-210 varies by country and region.<br> Key Features and Specifications to Evaluate <br>In case of cannabis or Δ9-tetrahydrocannabinol, there are many <ins style="font-weight: bold; text-decoration: none;">5CL ADBA powder </ins>previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998). After administering test substances once every other day for 10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day, and the first trial was performed 2 h after the last administration.<br> How to Choose Powder JWH-210 <br>This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based research.<br> Is JWH-210 Legal? <br>A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively. After the first injection, 6 mice of the positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance<ins style="font-weight: bold; text-decoration: none;"><br><br><br>After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand 5CL ADBA powder at room temperature for 5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates<br><br> 4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br> Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the [https://cannabinoidsrc4f-adb.com/ 5CL ADBA powder] highest dose tested (0.5 mg/kg).<br> Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic</ins></div></td></tr> </table>

ChongRede5